Publications

Peer Reviewed Publications

Journal Article

Published

  1. Thomson B, Joseph G, Clark WF, Hladunewich M, Patel A, Blake P, Eastabrook G, Matsui D, Sharma A and House A. Maternal, pregnancy and fetal outcomes in de novo anti-glomerular basement membrane antibody disease in pregnancy: a systematic review. Clinical Kidney Journal, 2014 Aug 14, Coauthor
  2. Rosansky S, Durkin M, Hardin J, Jackson K, Kovesdy C, Sontrop J, Reynolds J, Haddock K, Richards F, Clark WF. Relationship of race and proteinuria to renal function decline in patients with CKD. doi.org/10.4172/216.1-0959.1000168, Senior Responsible Author
  3. Dahlan R, McCormick BB, Alkhattabi M, Gallo K, Clark WF, Rock G. Patients’ quality of life after stopping plasma exchange: A pilot study. S1473-0502 (14)00103-7 DOI: 10.1016/j.transci2014.04.012, Principal Author, DOI: 10.1016/j.transci.20.
  4. Clark WF, Huang SH, Garg AX, House A, Moist LM, Weir M, Sontrop JM. “Drink at least 8 glasses of water a day to be healthy???”. Home Healthc Nurse, 2014 Apr 1; 32 (4): 237-42, Principal Author, DOI: 10.1097/NHH.00000000.
  5. Weir MA, Fleet JL, Vinden C, Shariff SZ, Liu K, Song H, Jain AK, Gandhi S, Clark WF, Garg AX. Hyponatremia and Sodium Picosulfate Bowel Preparations in Older Adults. Am J Gastroenterol, 2014 Mar 4, Coauthor, DOI: 10.1038/ajg.2014.20.
  6. Hildebrand AM, Huang SH, Clark WF. Plasma Exchange for Kidney Disease: What Is the Best Evidence? Adv Chronic Kidney Dis, 2014 Mar 1; 21 (2): 217-227, Senior Responsible Author, DOI: 10.1053/j.ackd.2014.
  7. Nesrallah GE, Mustafa RA, Clark WF, Bass A, Barnieh L, Hemmelgarn BR, Klarenbach S, Quinn RR, Hiremath S, Ravani P, Sood MM, Moist LM. Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. CMAJ, 2014 Feb 4; 186 (2): 112-7, Coauthor, DOI: 10.1503/cmaj.130363.
  8. Sockett P, Goebel SE, Varela NP, Guthrie A, Wilson J, Guilbault LA, Clark WF. Verotoxigenic Escherichia coli: Costs of Illness in Canada, Including Long-Term Health Outcomes. J Food Prot, 2014 Feb 1; 77 (2): 216-26, Senior Responsible Author, DOI: 10.4315/0362-028X.JF.
  9. Bouby N, Clark WF, Roussel R, Taveau C, Wang CJ. Hydration and kidney health. Epub. 2014 April 4, Senior Responsible Author, DOI: 10.1159/000360889.
  10. Nachman PH, Clark WF and Derebail V. Syllabus - NephSAP. NephSAP, 2014 Jan; 13 (1): 1-36, Co-Principal Author
  11. Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Weir MA, Garg AX. The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial. BMJ open, 2013 Dec 20; 3 (12): e003666, Principal Author, DOI: 10.1136/bmjopen-2013-003666.
  12. Jain AK, Sontrop JM, Perl J, Blake PG, Clark WF, Moist LM. Timing of Peritoneal Dialysis Initiation and Mortality: Analysis of the Canadian Organ Replacement Registry. Am J Kidney Disease. 2013 Dec 11. pii: S0272-6386(13)01441-8. doi: 10.1053/j.ajkd.2013.10.054. [Epub ahead of print], Coauthor, DOI: 10.1053/j.ajkd.2013.10.054.
  13. Nevis IF, Sontrop JM, Clark WF, Huang A, McDonald S, Thabane L, Moist L, Macnab JJ, Suri R, Garg AX. Hypertension in pregnancy after Escherichia coli O157:H7 gastroenteritis: a cohort study. Hypertens Pregnancy. 2013 Nov;32(4):390-400. Epub 2013 July 11, Coauthor
  14. Rosansky SJ, Cancarini G, Clark WF, Eggers P, Germaine M, Glassock R, Goldfarb DS, Harris D, Hwang SJ, Imperial EB, Johansen KL, Kalantar-Zadeh K, Moist LM, Rayner B, Steiner R, Zuo L. Dialysis Initiation: What’s the Rush? doi: 10.1111/sdi.12134 [Epub ahead of print], Coauthor
  15. Filler G, Clark WF, Huang S-HS. Tandem hemodialysis and plasma exchange. epub ahead of print, Coauthor
  16. Rosansky SJ, Clark WF. Has the yearly increase in the renal replacement therapy population ended? Epub 2013 July 18, Coauthor, DOI: 10.1681/ASN.2013050458.
  17. Wilson B, Sontrop JM, Clark WF. Choice of GFR estimating equation influences dialysis initiation and mortality. Nephrology nursing journal : journal of the American Nephrology Nurses’ Association, 2013 Jul 1; 40 (4): 339-46; quiz 347, Coauthor
  18. Rock G, Clark WF, Anderson D, Benny B, Sutton D, Leblond R, Sternbach M, Sontrop J and the Members of the Canadian Apheresis Group. ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura. Thromb Res. 2013 Apr;131(4). Epub 2013 Feb 11, Coauthor
  19. Walsh W, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, Dezoysa J, Ives N, Clark WF, Quillen K, Winters JL, Wheatley K, Jayne D; PEXIVAS Investigators. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013 Mar 14;14:73. Coauthor
  20. Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Dohein O, Huang S-H S, Clark WF. Association between water intake, chronic kidney disease, and cardiovascular disease: A cross-sectional analysis of NHANES data. American Journal of Nephrology 2013;37:434-442. Impact Factor: 2.68, Senior Responsible Author
  21. Ellwood AD, Jassal SV, Suri RS, Clark WF, Na Y, Moist LM. Early Dialysis Initiation on Rates and Timing of Withdrawal from Dialysis in Canada. Clinical Journal of the American Society of Nephrology. 2013 Feb; 8:265-270. Epub 2012 Oct 18, Coauthor
  22. Hizo-Abes P, Clark WF, Sontrop JM, Young A, Huang A, Thiessen-Philbrook H, Austin PC, Garg AX; Walkerton Health Study Investigators. Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis. CMAJ. 2013 Jan 8;185(1):E70-7.  Epub 2012 Nov 19, Coauthor
  23. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM, Barnato SE, Winters JL, Cursio JF, Weiss I, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen H, Chen F, Armstrong JM, Raisch DW, Bennett CL. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov;38(8):845-53.  Epub 2012 Oct 30, Coauthor
  24. 24.          Clark WF. The road to Hell is paved with good intentions. Semin Dial. 2012 Sep-Oct;25(5):520-1    Epub 2012 Jul 24, Principal Author
  25. Hildebrand AM, Iansavichus AV, Lee CW, Haynes RB, Wilczynski NL, McKibbon KA, Hladunewich MA, Clark WF, Cattran DC, Garg AX. Glomerular disease search filters for Pubmed, Ovid Medline, and Embase: a development and validation study. BMC Medical Informatics and Decision Making. Biomed Central; 2012, 12:49, Coauthor, DOI: 10.1186/1472-6947-12-49.
  26. Clark WF. Plasma Exchange for Renal Disease: Evidence and Use 2011. Journal of Clinical Apheresis 27:112-116.  Epub 2012 Apr 25, Principal Author
  27. Clark WF. Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange. Seminars in Dialysis; Therapeutic Apheresis for Nephrologists. 2012. 25(2)214-219.  Epub 2012 Feb 7, Principal Author
  28. 28.          Thabane M,   Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Marshall JK. Clustering and Stability of Functional Lower Gastrointestinal Symptom After Enteric Infection. Neurogastroenterol Motil. 2012 Jun;24(6):546-52.   Epub 2012 Feb 23, Collaborator
  29. Huang SH, Xenocostas A, Moist L, Crowther M, Moore JC, Clark WF. Case Report: Ustekinumab Associated Thrombotic Thrombocytopenic Purpura: Ustekinumab Associated TTP. Transfus Apher Sci. 2012 Oct;47(2):185-8.   Epub 2012 Aug 1, Senior Responsible Author
  30. Clark WF, Hildebrand A. Attending Rounds: Microangiopathic hemolytic anemia with renal insufficiency. CJASN . 2012 Feb;7(2); 342-347. Principal Author
  31. Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 6: 2634-2641, 2011.   Epub 2011 Sep 1, Principal Author, DOI: 10.2215/CJN.01990211.
  32. Clark WF, Macnab JJ, Sontrop JM, Jain AK, Moist L, Salvadori M, Suri R, Garg AX. Dipstick Proteinuria as a Sceening Straegy to Identify Rapid Renal Decline. Journal of the American Society of Nephrology. 2011 Sep 15; 22 (9): 1729-1736, Principal Author
  33. Huang S-HS, Hildebrand A, Clark WF. Brief Review: Management of Lupus Nephritis - Randomized Controlled Trials: An Update. Open Journal of Internal Medicine. 2011 Sep; 1:17-23  doi:10.4236/ojim.2011.12006 Published online Sept. 2011. Senior Responsible Author
  34. Rosansky S, Glassock R, Clark WF. In-Depth Review: Early Start of Hemodialysis - A Critical Review. CJASN. 2011, May;6(5) 1222-8, Senior Responsible Author
  35. Rosansky S, Eggers P, Jackson K, Glassock R and Clark WF. Early Start of Hemodialysis May Be Harmful. Archives of Internal Medicine. 2011 Mar 14; 171 (5): 396-403, Senior Responsible Author
  36. Huang SH, Sharma AP, Yasin A, Lindsay RM, Clark WF, Filler G. Hyperfiltration affects accuracy of creatinine eGFR measurement. Clin J Am Soc Nephrolo 6(2): 274-280, February, 2011. Coauthor, DOI: 10.2215/CJN.02760310.
  37. Wyne A, Raman R, Cuerden M, Clark WF, Suri RS. Opioid and Benzodiazepine Use in End Stage Renal Disease: A Systematic Review. CJASN.2011 Feb 6(2):326-333. Impact Factor: 4.84, Coauthor
  38. Clark WF, Na Y, Rosansky SJ, Sontrop JM, Macnab JJ, Glassock RJ, Eggers P, Jackson K and Moist L. Association between estimated glomerular filtration rate at initiation of dialysis and mortality. CMAJ Jan 11, 2011 Jan 11; 183 (1): 47-53, Principal Author
  39. Huang SS, Macnab JJ, Sontrop JM, Filler G, Gallo K, Lindsay RM, Clark WF. Performance Of The Creatinine-Based And The Cystatin C-Based GFR Estimating Equations In A Heterogenous Sample Of Patients Referred For Nuclear GFR Testing. Translational Research Jun, 2011; 157 (6): 357-367, 2011, Senior Responsible Author
  40. Jolly US, Shih A, Moist L, Clark W and Gabril M. Influenza a H1N1, Microscopic Polyangiitis and Pulmonary Haemorrhage. Nephrology (Carlton, 2010 Dec; 15 (8): 781, Coauthor
  41. Clark WF, Sontrop JM, Macnab JJ, Salvadori M, Moist L, Suri R, Garg AX. Long-term Risk for Hypertension, Renal Impairment and Cardiovascular Disease after  gastroenteritis from drinking water contaminated with Escheria coli 0157:H7: a prospective cohort study. British Medical Journal  e-pub.2010 Nov 17;341:c6020 doi:10.1136/bmj.c6020, Principal Author
  42. Sharma AP, Filler G, Dwight P, Clark WF. Chronic renal disease is more prevalent in patients with hemolytic uremic syndrome who had a positive history of diarrhea. Kidney International (2010) 78(6),598-604. Senior Responsible Author, DOI: 10.1038/ki.2010.174.
  43. Moist L, Sontrop JM, Garg AX, Clark WF, Suri RS, Gratton R, Salvadori M, Nevis I, Macnab JJ. Risk of pregnancy-related hypertension within 5 years of exposure to drinking water contaminated with Escherichia coli O157:H7. J Clin Hypertens (Greenwich), 2010 Aug 1; 12 (8): 613-20, Coauthor, DOI: 10.1111/j.1751-71760.
  44. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut, 2010 May 1; 59 (5): 605-11, Coauthor, DOI: 10.1136/gut.2009.
  45. Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology, 2010 May 1; 138 (5): 1727-36; quiz e12, Coauthor, DOI: 10.1053/j.gast.2010.
  46. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology, 2010 Apr 1; 138 (4): 1502-13, Coauthor, DOI: 10.1053/j.gast.2009.
  47. Robinson A, Clark WF. A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura). J Gastrointest Cancer, 2010 Mar 1; 41 (1): 71-4, Senior Responsible Author, DOI: 10.1007/s12029-009.
  48. Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Collins SM, Salvadori M, Marshall JK. An Outbreak of Acute Bacterial Gastroenteritis Is Associated with an Increased Incidence of Irritable Bowel Syndrome in Children. Am J Gastroenterology. 2010 Feb; 105 (4): 933-9, Coauthor
  49. Lam NN, Jain AK, Hackam DG, Cuerden MS, Suri RS, Huo CY, Li P, Clark WF, Garg AX. Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney International 2009;76(11), 1172-1179, Coauthor, DOI: 10.1038/ki.2009.323.
  50. Rock GA, Clark WF. Mechanism of microthrombosis in HUS. Kidney Int Suppl, 2009 Feb 1 (112): S15-6, Senior Responsible Author, DOI: 10.1038/ki.2008.611.
  51. Garg AX, Salvadori M, Moist LM, Suri RS and Clark WF. Renal prognosis of toxigenic Escherichia coli infection. Kidney Int. 2009 Feb; 75 (S112): S38-41, Senior Responsible Author
  52. Suri RS, Mahon JL, Clark WF, Moist LM, Salvadori M and Garg AX. Relationship between Escherichia coli O157:H7 and diabetes mellitus. Kidney Int. 2009 Feb; 75 (S112): S44-46, Coauthor
  53. Moist LM, Sontrop JM, Garg AX, Clark WF, Suri RS, Salvadori M, Gratton RJ and Macnab JJ. Risk of pregnancy-related hypertension within five years of exposure to bacteria-contaminated drinking water. Kidney Int. 2009 Feb; 75 (S112): S47-49, Coauthor
  54. Clark WF, Forzley BR, Sontrop JM, Kadri A, Moist LM, Suri RS, Salvadori MI and Garg AX. TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials. Kidney Int. 2009 Feb; 75 (S112): S50-51, Principal Author
  55. Salvadori M, Sontrop JM, Garg AX, Truong J, Suri RS, Mahmud FH, Macnab JJ, Clark WF. Elevated blood pressure in relation to overweight and obesity among children in a rural Canadian community. Pediatrics, 2008 Oct 1; 122 (4): e821-7, Senior Responsible Author, DOI: 10.1542/peds.2008.
  56. Forzley BR, Sontrop JM, Macnab JJ, Chen S, Clark WF. Treating TTP/HUS with plasma exchange: a single centre’s 25-year experience. British Journal of Haematology. 2008 October;143:100-106. Trainee Publication, Senior Responsible Author, DOI: 10.1111/1365-2141.
  57. Clark WF, Sontrop JM. What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials? Clin J Am Soc Nephrol, 2008 May 1; 3 (3): 895-8, Principal Author, DOI: 10.2215/CJN.00170108.
  58. Garg AX, Salvadori M, Okell JM, Thiessen-Philbrook HR, Suri RS, Filler G, Moist L, Matsell D, Clark WF. Albuminuria and estimated GFR 5 years after Escherichia coli O157 hemolytic uremic syndrome: an update. Am J Kidney Dis, 2008 Mar 1; 51 (3): 435-44, Senior Responsible Author, DOI: 10.1053/j.ajkd.2007.
  59. Garg AX, Pope JE, Thiessen-Philbrook H, Clark WF, Ouimet J, Walkerton Health Study Investigators. Arthritis risk after acute bacterial gastroenteritis. Rheumatology (Oxford), 2008 Feb 1; 47 (2): 200-4, Coauthor, DOI: 10.1093/rheumatology.
  60. Clark WF, Kortas C, Suri RS, Moist LM, Salvadori M, Weir MA, Garg AX, WEL Investigators. Excessive fluid intake as a novel cause of proteinuria. Canadian Medical Association Journal eLetter. 2008 January, 178(2):173-175. DOI: 10.1503/cmaj.070792.
  61. Clark WF,  Kortas C, Suri RS, Moist LM, Salvadori M, Weir MA, Garg AX; WEL Investigators. Excessive Fluid Intake as A Novel Cause of Proteinuria. CMAJ. 2008 Jan; 178 (2): 173-175, Principal Author
  62. Wilson B, Harwood L, Locking-Cusolito H, Chen SJ, Heidenheim P, Craik D, Clark WF. Optimal timing of initiation of chronic hemodialysis? Hemodialysis international. International Symposium on Home Hemodialysis, 2007 Apr 1; 11 (2): 263-9, Senior Responsible Author
  63. Wilson B, Harwood L, Locking-Cusolito H, Chen SJ, Heidenheim P, Craik D, Clark WF. Optimal timing of initiation of chronic hemodialysis? Hemodialysis international. International Symposium on Home Hemodialysis, 2007 Apr 1; 11 (2): 263-9, Coauthor
  64. Garg AX, Clark WF, Salvadori M, Thiessen-Philbrook HR, Matsell D. Absence of renal sequelae after childhood Escherichia coli O157:H7 gastroenteritis. For the Walkerton Health Study Investigators.  Kidney International. 2006;70 :807-812, Coauthor, DOI: 10.1038/sj.ki.500164.
  65. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM, Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445-450. Coauthor
  66. Clark WF, Macnab JJ, Chen SJ, Suri R, Moist L, Garg AX. Evaluation of GFR estimating equations in the general community: implications for screening. Clin J Am Soc Nephrol, 2006 Jul 1; 1 (4): 787-95. Trainee Publication, Principal Author, DOI: 10.2215/CJN.00140106.
  67. Rock G, Clark W, Sternbach M, Kolajova M, McLaine P. Haemolytic uraemic syndrome is an immune-mediated disease: role of anti-CD36 antibodies. British journal of haematology, 2005 Oct 1; 131 (2): 247-52, Coauthor
  68. Garg AX, Moist L, Matsell D, Thiessen-Philbrook HR, Haynes RB, Suri RS, Salvadori M, Ray J, Clark WF, Walkerton Health Study Investigators. Risk of hypertension and reduced kidney function after acute gastroenteritis from bacteria-contaminated drinking water. CMAJ, 2005 Aug 2; 173 (3): 261-8, Senior Responsible Author, DOI: 10.1503/cmaj.050581.
  69. Rock G, Anderson D, Clark W, Leblond P, Palmer D, Sternbach M, Sutton D, Wells G, Canadian Apheresis Group, Canadian Association of Apheresis Nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. British journal of haematology, 2005 Apr 1; 129 (1): 79-86, Coauthor
  70. Garg AX, Clark WF, Salvadori M, Macnab J, Suri RS, Haynes RB, Matsell D-for Walkerton Health Study Investigators. Microalbuminuria 3 years after recovery from E. coli O157 Hemolytic Uremic Syndrome due to municipal water contamination. Kidney International Apr, 2005 Apr; 67 (4): 1476-82. Trainee Publication, Coauthor
  71. Garg AX, Macnab JJ, Clark WF, Ray JG, Marshall JK, Suri RS, Devereaux PJ, Haynes RB for Walkerton Health Study Investigators. Long-term sequelae following E. coli and Campylobacter contamination of municipal water.  Population sampling and assessing non-participation biases. Canadian Journal of Public Health Mar-Apr, 2005 Mar; 96 (2): 125-30, Coauthor
  72. Garg AX, Moist L, Matsell D, Thiessen-Philbrook HR, Haynes RB, Suri RS, Salvadori M, Ray J, Clark WF - for the Walkerton Health Study Investigators. Risk of hypertension and reduced kidney function after acute gastroenteritis from bacteria-contaminated drinking water. Canadian Medical Accosiation Journal. 2005; 173 (3): 261-8. Trainee Publication, Senior Responsible Author
  73. Marshall JK, Thabane M, Garg A, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther, , Dec, 2004; 20 (11-12): 1317-22, Coauthor
  74. Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim AP, Sackett DL. Effect of awareness of a randomized controlled trial on use of experimental therapy. Journal of the American Medical Association 290:1351-1355, 2003. Trainee Publication, Principal Author, DOI: 10.1001/jama.
  75. Clark WF, Garg AX, Sackett D. Premature application of trial results to clinical practice. JAMA, 2003 Jan; 290 (23): 3072, Principal Author
  76. Garg AX, Kiberd B, Clark WF, Haynes R, Clase C. The Prevalence of albuminuria and renal insufficiency guide population screening. Kidney International, 2003; 64 (2): 761-2, Coauthor
  77. Rock G, Clark B, Sutton D, and Members of the CAG and CAAN. The Canadian Apheresis Registry. Transfusion and Apheresis Science 29 (2003) 167-177, Coauthor
  78. Allan DS, Thompson CM, Barr RM, Clark WF, Chin-Yee IH. Ciprofloxacin-associated hemolytic-uremic syndrome. Annals of Pharmacotherapy 36:1000-1002,2002. Trainee Publication, Coauthor
  79. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney International 61:1486-1494,  2002. Coauthor, DOI: 10.1046/j.1523-1755.
  80. Garg AX, Clark WF, Haynes RB, House A. Chronic renal insufficiency and cardiovascular disease. Kidney International, 2002; 62 (4): 1474-5, Coauthor
  81. Garg A, Kiberd B, Clark W, Haynes B, Clase C. Albuminuria and renal insufficiency guides population screening: Results from the NHANES III. Kidney International, 2002;61:2165-2175. Trainee Publication, Coauthor
  82. Garg AX, Blake PG, Clark WF, Clase CM, Haynes RB, Moist LM. Association between renal insufficiency and malnutrition in older adults: results from the NHANES III. Kidney International 60:1867-1874,2001. Trainee Publication, Coauthor, DOI: 10.1046/j.1523-1755.
  83. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. Canadian Medical Association Journal 162:195-198,2000. Principal Author
  84. Clark WF, Muir AD, Westcott ND, Parbtani A. A novel treatment for lupus nephritis: lignan precursor derived from flax. Lupus International 9:1-8,2000. Principal Author
  85. Cohen BA, Clark WF. Pauci-immune renal vasculitis:  Natural history, prognostic factors, and impact of therapy in 94 patients since 1984. American Journal of Kidney Diseases 36:914-924,2000. Trainee Publication, Coauthor
  86. Clark WF, Rock GA, Buskard N, Shumak KH, LeBlond P, Anderson D, Sutton DM. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Annals of Internal Medicine 131:453-462,1999. Principal Author
  87. Moist L, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Clinical & Investigative Medicine (Suppl) S67,#311,1998. Trainee Publication, DOI: 13424.
  88. Moist LM, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. American Journal of Nephrology 19:45-50,1999. Trainee Publication, Senior Responsible Author
  89. Leblond PF, Rock G, Herbert CA and the Canadian Apheresis Group. The use of plasma as a replacement fluid in plasma exchange. Transfusion 38:834-838,1998. Collaborator
  90. Ingram AJ, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ, Scholey JW. Dietary alteration of dihomogamma-linolenic acid/arachidonic acid ratio in a rat 5/6-renal-ablation model. The Nutrition & Kidney Disease Research Group. Journal of the American Society of Nephrology 7:1024-1031,1996. Trainee Publication, Coauthor
  91. Parbtani A, Clark WF, Paul LC. Flaxseed in experimental chronic renal transplant rejection. Proceedings of the 56th Flax Institute of the United States 56:25-35,1996. Coauthor
  92. Clark WF, Parbtani A. Flaxseed in experimental and clinical lupus nephritis. Proceedings of the 56th Flax Institute of the United States 56:17-24,1996. Principal Author
  93. Ingram AJ, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ. Effects of flaxseed and flax oil diets in a rat-5/6 renal ablation model. American Journal of Kidney Diseases 25:320-329,1995. Trainee Publication, Coauthor
  94. Shumak KH, Rock GA, Nair RC and the Canadian Apheresis Group. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Annals of Internal Medicine 122:569-572,1995. Collaborator
  95. Tomobe K, Philbrick D, Aukema HM, Clark WF, Ogborn MR, Parbtani A, Takahashi H, Holub BJ. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. Journal of the American Society of Nephrology 5:1355-1360,1994. Trainee Publication, Coauthor
  96. Clark WF. Treatment of lupus nephritis: immunosuppression, general therapy, dialysis and transplantation. Clinical Investigations in Medicine 17:588-601,1994. Principal Author
  97. Parbtani A, Clark WF. Flaxseed and its constituents in experimental renal disease. Proceedings of the 55th Flax Institute of the United States: 39-42,1994. Senior Responsible Author
  98. Tandon NN, Rock G, Jamieson G and the Canadian Apheresis Study Group. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. British Journal of Haematology 88:816-825,1994. Collaborator
  99. Hall AV, Parbtani A, Clark WF, Spanner E, Keeney M, Chin-Yee I, Philbrick DJ, Holub BJ. Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. American Journal of Kidney Diseases 22:326-332,1993. Trainee Publication, Coauthor
  100. Clark WF, Parbtani A, Philbrick DJ, Spanner E, Huff MW, Holub BJ. Dietary protein restriction versus fish oil supplementation in the chronic remnant nephron model. Clinical Nephrology 39:295-304,1993. Principal Author
  101. Hall AV, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. Journal of the American Society of Nephrology 3:1321-1329,1992. Trainee Publication, Coauthor
  102. Hall AV, Clark WF, Parbtani A. Heparin-induced thrombocytopenia in renal failure. Clinical Nephrology 38:86-89,1992. Trainee Publication, Coauthor
  103. Cole E, Cattran D, Magil A, Greenwood C, Churchill DN, Sutton D, Clark WF, Morrin P, Posen G, Bernstein K, Dyck R and the Canadian Apheresis Study Group. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. American Journal of Kidney Diseases 20:261-269,1992. Coauthor
  104. Schlieper A, Rowe PC, Orrbine E, Zoubek M, Clark WF, Wolfish N, Mclaine PN. Sequelae of haemolytic uremic syndrome. Archives of Disease in Childhood 67:930-934,1992. Coauthor
  105. Rock G, Buskard N, Leblond P, Shumak K, Sutton D, Hashemi S and the Canadian Apheresis Study Group. Target antigens of anti-platelet antibodies in patients with steroid-resistant ITP of recent onset. International Journal of Hematology 56:225-232,1992. Collaborator
  106. Rock G, Shumak K, Kelton J, Blanchette VS, Buskard N, Nair R, Spasoff R and the Canadian Apheresis Study Group. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 32:710-714,1992. Collaborator
  107. Clark WF, Parbtani A, Philbrick DJ, Holub BJ, Huff MW. Chronic effects of omega-3 fatty acids (fish oil) in a rat 5/6 renal ablation model. Journal of the American Society of Nephrology 1:1343-1353,1991. Principal Author
  108. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA and the Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. The New England Journal of Medicine 325:393-397,1991. Collaborator
  109. Clark WF, Parbtani A, Philbrick D, McDonald JW, Smallbone B, Reid B, Holub BJ, Kreeft J. Comparative efficacy of dietary treatments on renal function in rats with sub-total nephrectomy: renal polyunsaturated fatty acid incorporation and prostaglandin excretion. Clinical Nephrology 33:25-34,1990. Principal Author
  110. Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P. Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney International 36:653-660,1989. Principal Author
  111. Clark WF, Naylor CD. The role of platelets in progressive glomerulosclerosis: mechanisms for intraglomerular platelet activation and pathogenetic consequences. Medical Hypotheses 28:51-56,1989. Principal Author
  112. Eddy AA, Geary DF, Balfe JW, Clark WF, Baumal R. Prolongation of acute renal failure in two patients with hemolytic uremic syndrome due to excessive plasma infusion therapy. Pediatric Nephrology 3:420-423,1989. Coauthor
  113. Jevnikar AM, Petric R, Holub BJ, Philbrick DJ, Clark WF. Effect of cyclosporine on plasma lipids and modification with dietary fish oil. Transplantation 46:722-725,1988. Senior Responsible Author
  114. Bennett JD, Dubeau RA, Driedger AA, Clark WF, Morrissey GJ. Polymorphonuclear leukocytes labeled with technetium-99m HMPAO. A potential bone marrow imaging agent. Clinical Nuclear Medicine 13:44-45,1988. Coauthor
  115. Clark WF. The kidney in systemic disease. Urinary Systems 1. Medicine North America 27:4993-5006,1988. Principal Author
  116. Parbtani A, Clark WF, Caveney A, Reid B. Binding of aggregated immunoglobulins to the human platelet Fc receptors: a mechanism of platelet to platelet bridging. Thrombosis & Haemostasis 58:966-970,1987. Coauthor
  117. Clark WF, Parbtani A, McDonald JW, Taylor N, Reid BD, Kreeft J. The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse. Clinical Nephrology 28:288-294,1987. Principal Author
  118. Clark WF, Tevaarwerk GJ, Plomley RF, Reid BD, Parbtani A. Spontaneous aggregates of immunoglobulin-G prime the human platelet release reaction induced by close cell contact. Thrombosis Research 47:709-717,1987. Principal Author
  119. Clark WF, Tevaarwerk GJ, Reid BD, Hall S, Caveney A, Parbtani A, Kreeft J. Calcium and the Fc receptor on human platelets. Thombosis & Haemostasis 57:298-301,1987. Principal Author
  120. Parbtani A, Clark WF, Cameron JS. Pathogenic significance of platelet activation in lupus nephritis. Transplantation Proceedings XVIII: 657-661,1986. Coauthor
  121. Clark WF, Tevaaarwerk GJM, Reid BD, Parbtani A. Mechanism of intra-renal platelet release. Transplantation Proceedings XVIII: 662-663, 1986. Principal Author
  122. Linton AL, Richmond JM, Clark WF, Lindsay RM, Driedger AA, Lamki LM. Gallium67 scintigraphy in the diagnosis of acute renal disease. Clinical Nephrology 24:84-87,1985. Coauthor
  123. Toffelmire EB, Clark WF, Cordy PE, Linton AL, Lohmann RC. Plasma exchange in thrombotic thrombocytopenic purpura. Canadian Medical Association Journal 131:1371-1376,1984. Coauthor
  124. Bell DA, Rigby R, Stiller CR, Clark WF, Harth M, Ebers G. HLA antigens in systemic lupus erythematosus: relationship to disease severity, age at onset, and sex. Journal of Rheumatology 11:475-479,1984. Coauthor
  125. Tevaarwerk GJ, Clark WF, Rose CI, Moriarity TA, Hurst CJ. An ultrasensitive radioligand assay for IgG using the protein A on Staphylococcus aureus bacteria. Journal of Immunassay 5:267-274,1984. Coauthor, DOI: 10.1080/.
  126. Hood SA, Clark WF, Hodsman AB, Bolton CF, Cordy PE, Anderson C, Leung F. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol. American Journal of Nephrology 4:369-374,1984. Coauthor
  127. Clark WF, Balfe JW, Cattran DC, Williams W, Koval JJ, Arnott M, Chodirker WB, Lindsay RM, Linton AL. Long-term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis. Plasma Therapy & Transfusion Technology 5:353-360,1984. Principal Author
  128. Lindsay RM, Bolton CF, Clark WF, Linton AL. The effect of alterations of uremic retention products upon platelet and peripheral nerve function. Clinical Nephrology 19:110-115,1983. Coauthor
  129. Lindsay RM, Cvejich L, Muncaster D, Andrus F, Dennis B, Wong N, Clark WF, Linton AL. Evaluation of a combined hemodialysis and hemoperfusion system. Dialysis & Transplantation 12:764-776,1983. Coauthor
  130. Clark WF, Tevaarwerk GJ, Moriarity TA, Reid BD. Inhibitors of immune complex induced human platelet aggregation and release in plasma. Thrombosis Research 28:681-688,1982. Principal Author
  131. Clark WF, Tevaarwerk GJ, Reid BD. Human platelet-immune complex interaction in plasma. Clinical & Investigative Medicine 5:24b,1982.
  132. Clark WF. Primary glomerulonephritis: acute nephritis. Medicine North America 24:2411-2414,1982. Principal Author
  133. Clark WF, Tevaarwerk GJM, Reid BD. Human platelet-immune complex interaction in plasma. Journal of Laboratory & Clinical Medicine 100:917-931,1982. Principal Author
  134. Clark WF, Lindsay RM, Cattran DC, Chodirker WB, Barnes CC, Linton AL. Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study. Canadian Medical Association Journal 125:171-174,1981. Principal Author
  135. Clark WF, Lindsay RM, Ulan RA, Cordy PE, Linton AL. Chronic plasma exchange therapy in SLE nephritis. Clinical Nephrology 16:20-23,1981. Principal Author
  136. Clark WF, Reid BD, Tevaarwerk GJ. Anagrelide: inhibitor of collagen and forming immune complex induced platelet aggregation and release. Thrombosis Research 21:215-219,1981. Principal Author
  137. Linton AL, Clark WF, Driedger AA, Turnbull DI, Lindsay RM. Acute interstitial nephritis due to drugs: Review of the literature with a report of nine cases. Annals of Internal Medicine 93:735-741,1980. Coauthor
  138. Clark WF, Tevaarwerk GJ, Bandali K, Lindsay RM, Linton AL. Platelet aggregation and release associated with immune complex formation in pig plasma. Journal of Laboratory & Clinical Medicine 96:654-665,1980. Principal Author
  139. Rigby RJ, Driedger AA, Reid BD, Lindsay RM, Linton AL, Clark WF. Failure to demonstrate renal uptake of labelled platelets in chronic glomerulonephritis. Clinical Science 59:147-150,1980. Senior Responsible Author
  140. Clark WF, Reid BD, Dennis BN, Burka JF. Inhibition of platelet aggregation and release in a forming immune complex system. Thrombosis Research 19:687-693,1980. Principal Author
  141. Clark WF, Turnbull DI, Driedger AA, Lindsay RM, Linton AL. Intrarenal insoluble immune complex formation. Journal of Clinical Laboratory Immunology 4:21-25,1980. Principal Author
  142. Clark WF. Plasma exchange: a popular form of therapy. Dimens Health Serv, 1980 Jun 1; 57 (6): 26-8
  143. Clark WF. The rural to urban nutritional gradient: application and interpretation in a developing nation and urban situation. Soc Sci Med, 1980 Mar 1; 14D (1): 31-6
  144. Werb R, Clark WF, Lindsay RM, Jones EO, Linton AL. Serum vitamin A levels and associated abnormalities in patients on regular dialysis treatment. Clinical Nephrology 12:63-68,1979. Coauthor
  145. Werb R, Clark WF, Lindsay RM, Jones EO, Turnbull DI, Linton AL. Protective effect of prostaglandin [PGE2] and in glycerol-induced acute renal failure in rats. Clinical Science & Molecular Medicine 55:505-507,1978. Coauthor
  146. Lindsay RM, Friesen M, Aronstam A, Andrus F, Clark WF, Linton AL. Improvement of platelet function by increased frequency of hemodialysis. Clinical Nephrology 10:67-70,1978. Coauthor
  147. Aronstam A, Dennis B, Friesen MJ, Clark WF, Linton AL, Lindsay RM. Heparin neutralizing activity in patients with renal disease on maintenance haemodialysis. Thrombosis & Hemostasis (Stuttg) 39:696-700,1978. Coauthor
  148. Clark WF, Linton AL, Cordy PE, Keown PE, Lohmann RC, Lindsay RM. Immunologic findings, thrombocytopenia and disease activity in lupus nephritis. Digests International Editions 94,1979.
  149. Aronstam A, Dennis B, Friesen MN, Clark WF, Linton AL, Lindsay RM. Ristocetin and the thrombin clotting time. Journal of Clinical Pathology 31:1106-1110,1978. Coauthor
  150. Clark WF, Linton AL, Cordy PE, Keown PE, Lohmann RC, Lindsay RM. Immunologic findings, thrombocytopenia and disease activity in lupus nephritis. Canadian Medical Association Journal 118:1391-1394,1978. Principal Author
  151. Linton AL, Clark WF, Driedger AA, Werb R, Lindsay RM. Correctable factors contributing to the anemia of dialysis patients. Nephron 19:95-98,1977. Coauthor
  152. Linton AL, Lindsay RM, Clark WF, Werb R. Anemia in dialysis patients - inevitable or correctable? Clinical Dialysis and Transplant Forum 28,1976. Coauthor
  153. Clark WF, Friesen M, Linton AL, Lindsay RM. The platelet as a mediator of tissue damage in immune complex glomerulonephritis. Clinical Nephrology 6:287-289,1976. Principal Author
  154. Clark WF, Sullivan SN, Lindsay RM, Wang YL, Turnbull DI, Linton AL. Ascites secondary to transudation from a renal cadaveric transplant. Journal of the American Medical Association 235:635,1976. Principal Author
  155. Clark WF, Lewis ML, Cameron JS, Parsons V. Intrarenal platelet consumption in the diffuse proliferative nephritis of systemic lupus erythematosus. Clinical Science & Molecular Medicine 49:247-252,1975. Principal Author
  156. Oakley HF, Clark WF, Parsons V. The use of dialysis bath fluid as a vehicle for a drug with a narrow therapeutic index – lithium chloride. Postgraduate Medical Journal 50:511-512,1974. Coauthor
  157. Clark WF, Linton AL. The problem of analgesic nephropathy. Clinical Toxicology 6:33-43,1973. Principal Author, DOI: 10.3109/15563657308.

Accepted / In Press

  1. Farah M, Huang S, Hildebrand AM, Dammas H, Clark WF. Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in 2014 - Current Knowledge and Outcomes with Plasma Exchange. US Oncology & Hematology Review, 2014 Aug Senior Responsible Author

Book Chapter / Review Article

Published

  1. Clark WF. Plasma Exchange Not Found to Benefit Patients with Myeloma and Kidney Failure.; 2006. Oncology Times, 2006. Principal Author
  2. Clark WF, Ogborn M. Flaxseed and flaxseed lignans – Effects on the progression and severity of  renal failure.; 2003. Flax, The genus Linum, (AD Muir and ND Westcott, Eds).  Taylor & Francis, London U.K. Chapter 10:214-229, 2003. Principal Author
  3. Rehman F, Garg AX, Clark WF. Thrombotic thrombocytopenic purpura - Hemolytic uremic syndrome.; 2001. Canadian Journal of Continuing Medical Education 13;85-94,2001. Trainee Publication, Senior Responsible Author
  4. Clark WF. Pulmonary hemorrhage with rapidly progressive kidney failure.; 2001. Canadian Journal of Diagnosis 18:111-120,2001. Principal Author
  5. Clark WF. Myeloma kidney or cast nephropathy.; 2000. Education Program Book, International Society of Hematology 2000, pp 63-65. Principal Author
  6. Clark WF. What’s new in lupus nephritis?; 2000. Canadian Journal of CME 12;195-203,2000. Principal Author
  7. Rock G, Shumak K, Clark W. Apheresis in Canada: A national perspective.; 2000. Education Program Book, International Society of Hematology 2000, pp 55-58. Senior Responsible Author
  8. Clark WF. Update of plasma exchange in myeloma kidney study.; 1999. Canadian Apheresis Group Bulletin: June, 1999. Principal Author
  9. Clark WF. Medical Care News: Seeds of Hope.; 1996. Prevention (America’s Leading Health Magazine) Feb:48-49,1996, Principal Author
  10. Clark WF, Parbtani A. Flaxseed in experimental and clinical lupus nephritis.; 1996. Proceedings of the 56th Flax Institute of the United States 56: 17-24, 1996. Principal Author
  11. Parbtani A, Clark WF. Flaxseed and its components in renal diseases.; 1995. Flaxseed in Human Nutrition. Cunnane S and Thompson LU (eds). American Oil Chemists Society Press Publ. Champaign, Il, Chapter 17:244-260,1995. Senior Responsible Author
  12. Philbrick DJ, Jevnikar AM, Celi B, Petric R, Clark WF, Holub BJ. Effect of dietary fish oil on kidney phospholipids during cyclosporin treatment in rats.; 1989. Health Effects of Fish and Fish Oils. Chandra RK (ed). ARTS Biomedical Publ. St. John’s, Newfoundland Chapter 32:495-505,1989. Coauthor
  13. Clark WF, Parbtani A, Jevnikar AM. Fish oil therapy in kidney disease.; 1989. Health Effects of Fish and Fish Oils. Chandra RK (ed). ARTS Biomedical Publ. St. John’s, Newfoundland, Chapter 18:303-320,1989. Principal Author
  14. Clark WF, Spence JD. Drug dosage in renal failure.; 1988. Synopsis of Critical Care (3rd Ed). Sibbald WJ(ed). William & Wilkins Publ. Baltimore, MD, 129-133, 1988. Principal Author
  15. Clark WF, Spence JD. Drug dosage in renal failure.; 1984. Synopsis of Critical Care (2nd Ed). Sibbald WJ(ed). Williams & Wilkins Publ. Baltimore, MD, 127-1137,1984. Principal Author
  16. Clark WF. Plasmapheresis: A new/old form of therapy.; 1984. The Renal Family 6:11-14,1984. Principal Author
  17. Clark WF. Plasma exchange as a therapeutic adjunct.; 1981. Advances in Medicine, Diagnosis, Therapy, Concepts and Costs. Spence JD (ed) UWP Press, London, ON, 39-50,1981. Principal Author
  18. Lindsay RM, Richmond J, Burton H, Conley J, Clark WF, Linton AL. Is home dialysis too stressful?; 1981. Controversies in Nephrology. Charbray Publ. Washington, 3:395-405,1981. Coauthor
  19. Clark WF, Lindsay RM, Linton AL. Plasma exchange in lupus nephritis.; 1981. Controversies in Nephrology. Charbray Publ. Washington, 3:229-238,1981. Principal Author
  20. Linton AL, Lindsay RM, Clark WF. Assessment of iron status of patients with chronic renal failure.; 1980. Controversies in Nephrology. Charbray Publ. Washington, 2:376-385,1980. Senior Responsible Author
  21. Lindsay RM, Dennis BN, Clark WF, Linton AL. The continuing search for the uremic toxin. III Observations based upon the uremic platelet defect.; 1980. Controversies in Nephrology. Charbray Publ. Washington, 2:123-135, 1980. Coauthor
  22. Clark WF. Antibiotic dosage in renal failure.; 1980. Synopsis of Critical Care: practical management of the acutely ill. Sibbald WJ(ed). UWO Press, London, ON, 99-104,1980. Principal Author
  23. Lindsay RM, Clark WF, Linton AL. Platelets in SLE nephritis.; 1979. Controversies in Nephrology. Charbray Publ. Washington, 1:656-669,1979. Senior Responsible Author
  24. Clark WF. Alterations in drug therapy with renal failure.; 1977. Management of the Critically Ill Medical/Surgical Patient. Holliday R, Lobb T, Sibbald WJ(eds). UWO Press, London, ON, 67-76,1977. Principal Author
  25. Linton AL, Melendez LJ, Clark WF, Lindsay RM. Cardiovascular problems in regular dialysis treatment.; 1976. Regional Management of Terminal Renal Failure. Lindsay RM, Linton AL(eds). UWO Press, London, ON, 96-97,1976. Coauthor

Invited Editorial

Published

  1. Liberek T, Warzocha A, Galgowska J, Taszner K, Clark WF and Rutkowski B. When to initiate dialysis - is early start always better? Nephrol Dial Transplant, 2011 May; 26 (7): 2087-91, Coauthor
  2. Clark WF. HUS/TTP update: 2008. Kidney Int Suppl, 2009 Feb 1, DOI: 10.1038/ki.2008.607.

Letters to Editor

Published

  1. Clark WF, Rock GA. Validation of treatment strategies for enterohaemorrhagic Escheria coli O104:H4 induced haemolytic uraemic syndrome: case-control study. 2012 Aug 10. BMJ, 10 August 2012. Online, Coauthor
  2. Sharma AP, Filler G, Dwight P and Clark WF. Authors reply: Possible other causative risk factors in patients with chronic renal disease who had a history of hemolytic uremic syndrome. 2011 Jul 1. Kidney International  (2011)80(1),124. Senior Responsible Author
  3. Rosansky SJ, Clark WF. Low pre-dialysis serum creatinine level and increased incidence of sudden cardiac arrest: a possible explanation of the harm associated with early dialysis initiation. Kidney Int. 2011 Jun, 79. (11): p.1259, Coauthor
  4. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Reply to 56755. 2010 Dec. Gastroenterology. 2010 Dec. 20 [Epub ahead of print]. Coauthor
  5. Rosansky S, Eggers P, Clark WF and Glassock RJ. Response to “Early initiation of dialysis via percutaneous catheters”. 2010. Kidney International 2010, 77,367. Coauthor
  6. Rosansky S, Glassock RJ, Eggers PW and Clark WF. Response to “The CANUSA study and the importance of residual kidney function in dialysis patients”. 2010. Kidney International 2010, 77,931-932, Senior Responsible Author

Book Chapter / Review Article

Published

  1. Clark WF. Plasma Exchange Not Found to Benefit Patients with Myeloma and Kidney Failure. 2006. Oncology Times, 2006. Principal Author
  2. Clark WF, Ogborn M. Flaxseed and flaxseed lignans – Effects on the progression and severity of  renal failure. 2003. Flax, The genus Linum, (AD Muir and ND Westcott, Eds).  Taylor & Francis, London U.K. Chapter 10:214-229, 2003. Principal Author
  3. Rehman F, Garg AX, Clark WF. Thrombotic thrombocytopenic purpura - Hemolytic uremic syndrome. 2001. Canadian Journal of Continuing Medical Education 13;85-94,2001. Trainee Publication, Senior Responsible Author
  4. Clark WF. Pulmonary hemorrhage with rapidly progressive kidney failure. 2001. Canadian Journal of Diagnosis 18:111-120,2001. Principal Author
  5. Clark WF. Myeloma kidney or cast nephropathy. 2000. Education Program Book, International Society of Hematology 2000, pp 63-65. Principal Author
  6. Clark WF. What’s new in lupus nephritis? 2000. Canadian Journal of CME 12;195-203,2000. Principal Author
  7. Rock G, Shumak K, Clark W. Apheresis in Canada: A national perspective. 2000. Education Program Book, International Society of Hematology 2000, pp 55-58. Senior Responsible Author
  8. Clark WF. Update of plasma exchange in myeloma kidney study. 1999. Canadian Apheresis Group Bulletin: June, 1999. Principal Author
  9. Clark WF. Medical Care News: Seeds of Hope. 1996. Prevention (America’s Leading Health Magazine) Feb:48-49,1996, Principal Author
  10. Clark WF, Parbtani A. Flaxseed in experimental and clinical lupus nephritis. 1996. Proceedings of the 56th Flax Institute of the United States 56: 17-24, 1996. Principal Author
  11. Parbtani A, Clark WF. Flaxseed and its components in renal diseases. 1995. Flaxseed in Human Nutrition. Cunnane S and Thompson LU (eds). American Oil Chemists Society Press Publ. Champaign, Il, Chapter 17:244-260,1995. Senior Responsible Author
  12. Philbrick DJ, Jevnikar AM, Celi B, Petric R, Clark WF, Holub BJ. Effect of dietary fish oil on kidney phospholipids during cyclosporin treatment in rats. 1989. Health Effects of Fish and Fish Oils. Chandra RK (ed). ARTS Biomedical Publ. St. John’s, Newfoundland Chapter 32:495-505,1989. Coauthor
  13. Clark WF, Parbtani A, Jevnikar AM. Fish oil therapy in kidney disease. 1989. Health Effects of Fish and Fish Oils. Chandra RK (ed). ARTS Biomedical Publ. St. John’s, Newfoundland, Chapter 18:303-320,1989. Principal Author
  14. Clark WF, Spence JD. Drug dosage in renal failure. 1988. Synopsis of Critical Care (3rd Ed). Sibbald WJ(ed). William & Wilkins Publ. Baltimore, MD, 129-133, 1988. Principal Author
  15. Clark WF, Spence JD. Drug dosage in renal failure. 1984. Synopsis of Critical Care (2nd Ed). Sibbald WJ(ed). Williams & Wilkins Publ. Baltimore, MD, 127-1137,1984. Principal Author
  16. Clark WF. Plasmapheresis: A new/old form of therapy. 1984. The Renal Family 6:11-14,1984. Principal Author
  17. Clark WF. Plasma exchange as a therapeutic adjunct. 1981. Advances in Medicine, Diagnosis, Therapy, Concepts and Costs. Spence JD (ed) UWP Press, London, ON, 39-50,1981. Principal Author
  18. Lindsay RM, Richmond J, Burton H, Conley J, Clark WF, Linton AL. Is home dialysis too stressful? 1981. Controversies in Nephrology. Charbray Publ. Washington, 3:395-405,1981. Coauthor
  19. Clark WF, Lindsay RM, Linton AL. Plasma exchange in lupus nephritis. 1981. Controversies in Nephrology. Charbray Publ. Washington, 3:229-238,1981. Principal Author
  20. Linton AL, Lindsay RM, Clark WF. Assessment of iron status of patients with chronic renal failure. 1980. Controversies in Nephrology. Charbray Publ. Washington, 2:376-385,1980. Senior Responsible Author
  21. Lindsay RM, Dennis BN, Clark WF, Linton AL. The continuing search for the uremic toxin. III Observations based upon the uremic platelet defect. 1980. Controversies in Nephrology. Charbray Publ. Washington, 2:123-135, 1980. Coauthor
  22. Clark WF. Antibiotic dosage in renal failure. 1980. Synopsis of Critical Care: practical management of the acutely ill. Sibbald WJ(ed). UWO Press, London, ON, 99-104,1980. Principal Author
  23. Lindsay RM, Clark WF, Linton AL. Platelets in SLE nephritis. 1979. Controversies in Nephrology. Charbray Publ. Washington, 1:656-669,1979. Senior Responsible Author
  24. Clark WF. Alterations in drug therapy with renal failure. 1977. Management of the Critically Ill Medical/Surgical Patient. Holliday R, Lobb T, Sibbald WJ(eds). UWO Press, London, ON, 67-76,1977. Principal Author
  25. Linton AL, Melendez LJ, Clark WF, Lindsay RM. Cardiovascular problems in regular dialysis treatment. 1976. Regional Management of Terminal Renal Failure. Lindsay RM, Linton AL(eds). UWO Press, London, ON, 96-97,1976. Coauthor

Meta-Analysis Review

Published

  1. Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX. Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes care. 2005 Oct 1, 28. (10): p.2556-62. Trainee Publication, Coauthor

Letter, Published Erratum

Published

  1. Clark WF. Correction: Plasma exchange when myeloma presents as acute renal failure. Ann Intern Med. 2007 Mar 20, 146. (6): p.471

Presented Abstract

Published

  1. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON; Division of Nephrology and Kidney Research Unit, University of Western Ontario, London ON. Incidence of Inflammatory Bowel Disease Following the Walkerton Outbreak of Waterborne Bacterial Gastroenteritis. 2009 Dec 1. Digestive Disease Week. Ernest N. Morial Convention Center, New Orleans, LA, U.S.A.; May 1-5, 2010, Coauthor

Non-Peer Reviewed Publications

Journal Article

Published

  1. Garg AX, Clark WF, Salvadori M, Macnab J, Suri RS, Haynes RB, Matsell D, Walkerton Health Study Investigators. Microalbuminuria three years after recovery from Escherichia coli O157 hemolytic uremic syndrome due to municipal water contamination. Kidney Int, 2005 Apr 1; 67 (4): 1476-82, DOI: 10.1111/2005.
  2. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int, 2002 Jun 1; 61 (6): 2165-75, DOI: 10.1046/j.1523-1755.

Book Chapter / Review Article

Published

  1. Clark WF, Lindsay RM, Linton AL, Driedger AA, Brown P, Bernardo J. Anemia of the regular dialysis patient.; 1976. Regional Management of Terminal Renal Failure. Lindsay RM, Linton AL(eds), UWO Press, London, ON,48-53,1976. Principal Author
  2. Clark WF, Lindsay RM, Linton AL, Turnbull DI. Review of 100 cases of glomerulonephritis.; 1976. Regional Management of Terminal Renal Failure. Lindsay RM, Linton AL(eds), UWO Press, London, ON,176-186,1976. Principal Author

Commentaries

Published

  1. Bradshaw SE. Risk Factors: Patients infected with Escheria coli 0157:H7 face long-term health risks. 2010. Nature. February 2011; volume 7(2); 64. Quoted Research Author

Book Chapter / Review Article

Published

  1. Clark WF, Lindsay RM, Linton AL, Driedger AA, Brown P, Bernardo J. Anemia of the regular dialysis patient. 1976. Regional Management of Terminal Renal Failure. Lindsay RM, Linton AL(eds), UWO Press, London, ON,48-53,1976. Principal Author
  2. Clark WF, Lindsay RM, Linton AL, Turnbull DI. Review of 100 cases of glomerulonephritis. 1976. Regional Management of Terminal Renal Failure. Lindsay RM, Linton AL(eds), UWO Press, London, ON,176-186,1976. Principal Author

Periodical

Published

  1. Clark WF. Simple Urine Test detects Kidney Disease. 2011 Sep 28. Bottom Line Personal. Vol.31, Num 19; October 1, 2011. Principal Author

Abstracts

Abstracts Published

Peer Reviewed

Published

  1. Clark WF, Na Y, Rosansky SJ, Sontrop JM, Macnab JJ, Glassock RJ, Eggers P, Jackson K and Moist L. Higher eGFR at Dialysis Initiation is Associated with Increased Mortality; 2010. TH-FC044; Dialysis: Epidemiology and Outcomes. The 43rd Annual Meeting of the American Society of Nephrology, Denver, Colorado, U.S.A. November 18-21, 2010. Principal Author
  2. Wyne A, Raman R, Cuerden M, Clark WF, Suri RS. Opioid and Benzodiazepine Use in End Stage Renal Disease: A Systematic Review; 2010. CJASN. 6:326-333, February, 2011. Coauthor
  3. Clark WF, Macnab JJ, Salvadori MI, Matsell DG, Suri R, Moist LM, Kortas C, Garg AX. Association of Common Measures of Kidney Function; Year 1 and 2 of the Walkerton Screening Clinic.; 2004. Journal of the American Society of Nephrology.  Vol 15; Abstract Issue; PUB130:  October 2004. Principal Author
  4. Garg AX, Macnab J, Clark W, Ray JG, Marshall JK, Suri RS, Devereaux PJ, Haynes B. Long-Term Health Sequelae Following Municipal Water Contaminated with Escherichia Coli O157 and Campylobacter Species.; 2004. Journal of the American Society of Nephrology.  Vol 15; Abstract Issue; PUB067:  October 2004. Coauthor
  5. Clark WF, Stewart KA, Rock GA, Sternbach M, Sutton DM, Heidenheim PA, Churchill DN. Randomized Controlled Trial of Plasma Exchange Treatment in Myeloma Kidney.; 2004. Journal of the American Society of Nephrology.  Vol 15; Abstract Issue; SA-PO229:  October 2004. Principal Author
  6. Garg A, Clark W, Salvadori M, Macnab J, Suri R, Haynes B, Matsell D. Evidence of Long-Term Renal Sequelae 3 Years after E.Coli O157 Hemolytic Uremic Syndrome Following Municipal Water Contamination.; 2004. Journal of the American Society of Nephrology.  Vol 15; Abstract Issue; F-PO328:  October 2004. Coauthor
  7. Garland JS, Clase CM, Kiberd BA, Clark WF, Garg AX. Prevalence of low GFR and Proteinuria in the US adult population: National Health and Nutrition Examination Survey (NHANES 1999-2000).  How many people have CKD?; 2003. Journal of the American Society of Nephrology.  Vol 14; Abstract Issue; F-PO1026:  November, 2003. Coauthor
  8. Clark WF, Garg AZ, Howard J, Matsell DG, Moist LM, Salvadori MI, Macnab JJ. Walkerton Re-Visited.; 2003. Journal of the American Society of Nephrology.  Vol 14; Abstract Issue; SA-PO700:  November, 2003. Principal Author
  9. Wyllie BF, Garg, AX, Macnab J, Rock G, Clark, WF. Renal thrombotic Microangiopathies – HUS/TTP:  22 Years of CAG Experience.; 2003. Journal of the American Society of Nephrology.  Vol 14; Abstract Issue; SA-PO701:  November, 2003. Senior Responsible Author
  10. Lindsay RM, Kroeker A, Clark WF, Muirhead N. Conventional and home quotidian hemodialysis operating cost comparison.; 2003. Journal of the American Society of Nephrology.  Vol 14; Abstract Issue; SA-FC139:  November 2003. Coauthor
  11. Salvadori MI, Garg AX, Howard J, Clark WF, Matsell DG. An outbreak of E.coli 0157:H7 infections due to a contaminated municipal water supply in rural Ontario – Short term outcome of children developing HUS.; 2002. ASN (Philadelphia PA). Program & Abstracts,  Journal of the American Society of Nephrology 13: Abst #SU-P0940, p. 662A (Oct-Nov) 2002. Coauthor
  12. Garg AX, Suri RS, Rehman F, Salvadori M, Haynes B, Matsell DG, Clark WF. The influence of reported methodological quality on the results of long-term renal prognosis studies of diarrhea associated hemolytic uremic syndrome.; 2002. ASN  (Philadelphia PA) Journal of the American Society of Nephrology 13: Abst # PUB142, p. 699A (Oct-Nov) 2002. Senior Responsible Author
  13. Clark WF, Garg AX, Blake PG, Rock GA, Canadian Apheresis Group. Study awareness effect on utilization.; 2001. Journal of the American Society of Nephrology 12: Abst #A1019, p.196A,2001. Principal Author
  14. Garg AX, Blake PG, Clark WF, Clase CM, Haynes RB, Moist LM. The association between renal insufficiency and malnutrition in community-dwelling older adults.; 2001. Journal of the American Society of Nephrology 12: Abst #A1053, p.203A,2001. Coauthor
  15. Garg AX, Clark WF, Haynes RB, House AA. Is the association between moderate renal insufficiency and cardiovascular mortality causal?; 2001. Journal of the American Society of Nephrology 12: Abst #A1054, p.203-4A,2001. Coauthor
  16. Garg AX, Clark WF, Clase CM, Haynes RB, Kiberd BA. The prevalence of albuminuria in diabetics and non-diabetics with renal insufficiency.; 2001. Journal of the American Society of Nephrology 12: Abst #A1055, p.204A, 2001. Coauthor
  17. Moist LM, Markus H, Heidenheim AP, Mac Laren H, Clark WF. Predictors of tunneled dialysis catheter related bacteremia.; 2001. Journal of the American Society of Nephrology 12: Abst #A1529, p.297-8A,2001. Corresponding Author
  18. Allan DS, Clark WF. Recurrent  thrombocytopenic purpura treated with cytotoxic therapy.; 2000. International Journal of Haematology. Abst #16386, p.184,2000. Corresponding Author
  19. Rock GA, Sutton DM, Benny B, Clark B, Leblond P, Shumak K, Sternback M, Sutton A, Anderson D, Sheridan D, - Canadian Apheresis Group. Plasma therapy in thrombotic thrombocytopenic purpura (TTP).; 2000. International Journal of Haematology. Abst #15396, p.16,2000. Coauthor
  20. Clark WF, Rock GA, Buskard N, Shumak RH, Leblond P, Anderson D, Sutton DM. Therapeutic plasma exchange: An update from the Canadian Apheresis Group.; 2000. Proceedings, American Society for Aphersis. Abst #20, p.50,2000. Principal Author
  21. Clark WF, Muir AD, Westcott ND, Parbtani A:. A novel treatment for lupus nephritis: Lignan precursor derived from flax.; 1999. Journal  of the American Society of Nephrology 10:656A,#A3328,1999. Principal Author
  22. Cohen BA, Clark WF. Pauci-immune renal vasculitis: natural history, prognostic factors and response to therapy in 94 patients since 1984.; 1999. Journal of the American Society of Nephrology 10:99A,#A0506,1999. Coauthor
  23. Clark WF, Rock GA, Buskard NA, Shumak KH, Leblond P, Anderson D, Sutton DM. Canadian Apheresis Group recommended applications for plasma exchange.; 1998. Clinical & Investigative Medicine (Suppl) S66,#302,1998. Principal Author
  24. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To Pay or Not to pay? – A decision and cost-utility analysis from the state perspective of ACE-inhibitor therapy for diabetic nephropathy.; 1998. Journal of the American Society of Nephrology 9:143A,#A0738,1998. Principal Author
  25. Clark WF, Parbtani A, Macdonald G, Heidenheim P, Holub B, Kortas C. Flaxseed lupus nephritis: A two year randomized cross-over study.; 1998. Journal of the American Society of Nephrology 9:143A,#A0737,1998. Principal Author
  26. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To Pay or Not to Pay? – A decision and cost-utility analysis from the state perspective of ACE-inhibitor therapy for diabetic nephropathy.; 1998. Clinical & Investigative Medicine (Suppl) S72,#336,1998. Principal Author
  27. Matsell DG, Bennett T, Spangenberg H, Clark WF, Parbtani A. Alteration of the insulin-like growth factor (IGF) system in the nephritis of the MRL/lpr lupus mouse.; 1996. Clinical & Investigative Medicine 19:465,1996. Coauthor
  28. Clark WF, Parbtani A, Huff MW, Spanner E, Philbrick DY, Holub BJ. Flaxseed: A nutraceutical for lupus nephritis?; 1995. Clinical & Investigative Medicine 18:675,1995. Principal Author
  29. Parbtani A, De Salis H, Davidoff A, Huff MW, Philbrick DJ, Holub BY, Paul LC, Clark WF. Dietary flaxseed in a rat-chronic renal transplant rejection model.; 1995. Clinical & Investigative Medicine 18:632,1995. Corresponding Author
  30. Parbtani A, Clark WF, De Salis H, Rudzitis L, Keeney M, Chin-Yee I, Philbrick DJ, Holub BJ. Flaxseed and its constituents in MRL-lpr lupus mice.; 1994. Journal of the American Society of Nephrology A#28P,5:762,1994. Coauthor
  31. Clark WF, Parbtani A, De Salis H, Rudzitis L, Keeney M, Chin-Yee I, Philbrick DJ, Holub BJ. Flaxseed-derived lignan in MRL/lpr lupus mice.; 1994. Journal of the American Society of Nephrology 5:743,1994. Principal Author
  32. Clark WF, Parbtani A, De Salis H, Spanner E, Rudzitis L, Keeney M, Chin-Yee I, Huff MW, Philbrick DJ, Holub BH. Flaxseed dosing study in lupus nephritis patients.; 1994. Journal of the American Society of Nephrology A#119P,5:3348,1994. Principal Author
  33. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DV, Clark WF, Morrin PA, Lavoie S. A controlled trial of cyclosporine in patients with progressive membranous nephropathy (PMGN).; 1994. Clinical & Investigative Medicine A#605,17:B102,1994. Coauthor
  34. Parbtani A, Clark WF, De Salis H, Philbrick DJ, Holub BJ. Flaxseed and its constituents in murine lupus.; 1994. Clinical & Investigative Medicine A#578,17:B98,1994. Coauthor
  35. Clark WF, Parbtani A, De Salis H, Philbrick DJ, Holub BJ. Flaxseed derived lignans in murine lupus.; 1994. Clinical & Investigative Medicine A#577,17:B97,1994. Principal Author
  36. Cattran DC, Greenwood C, Ritchie K, Churchill DN, Clark WF, Morin PA, Grynoch R, Lavoie S for the Canadian Glomerulonephritis Study Group. A controlled trial of cyclosporine in patients with progressive membranous nephropathy.; 1993. Journal of the American Society of Nephrology A#118P,4:271,1993. Coauthor
  37. Ingram AJ, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ. Flax oil and flaxseed diets in a renal ablation model.; 1993. Journal of the American Society of Nephrology A#110P,4:771,1993. Coauthor
  38. Morrissey G, Ingram AJ, Parbtani A, Guiguero V, Clark WF. ACE-inhibitor uptake in 5/6 nephrectomized rats.; 1993. Journal of the American Society of Nephrology 4:518,1993. Senior Responsible Author
  39. Ingram AJ, Paarbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Mills DE, Scholey J, Holub BJ. Dietary change in DGLA:AA ratio in a 5/6 renal ablation model.; 1993. Journal of the American Society of Nephrology A#42P,4:455,1993. Coauthor
  40. Morrissey G, Ingram AJ, Parbtani A, Quiguero V, Clark WF. ACE-inhibitor analogue uptake in 5/6 nephrectomized rats.; 1993. Journal of the American Society of Nephrology. 4:518,1993. Senior Responsible Author
  41. Ingram AJ, Parbtanin A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ. Borage and corn oil diets in a rat-5/6 renal ablation model.; 1993. Clinical & Investigative Medicine (Suppl) A#671,16:B108,1993. Coauthor
  42. Ingram AJ, Parbtanin A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ. Flax oil and flaxseed diets in a rat-5/6 renal ablation model.; 1993. Clinical & Investigative Medicine (Suppl) A#671,16:B107,1993. Coauthor
  43. Ingram AJ, Parbtanin A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Mills DE, Scholey J, Holub BJ. Dietary change in DGLA:AA ratio in a 5/6 renal ablation model.; 1993. Journal of the American Society of Nephrology. A#42P, 4:455, 1993. Coauthor
  44. Hall AV, Parbtani A, Clark WF, Spanner E, Keeney M, Chin-Yee I, Philbrick DJ, Holub BJ. Flaxseed diet ameliorates nephritis in MRL/lpr mice.; 1992. Journal of the American Society of Nephrology A#101P,3:592,1992. Coauthor
  45. Clark WF, Parbtani A, Naylor CD, Muirhead N, Huff MW, Philbrick DJ, Holub, BJ, Kreeft J. Fish oil in lupus nephritis: A double/blind randomized crossover study.; 1992. Journal of the American Society of Nephrology A#37P,3:309,1992. Principal Author
  46. Tomobe K, Aukema H, Ogborn M Philbrick DJ, Takahashi H, Parbtani A, Clark WF, Holub BJ. Effects of protein restriction and type on disease progression in the DBA/2FG-pcy murine model of polycystic kidney disease (PKD).; 1992. Journal of the American Society of Nephrology A#116P,3:303,1992. Coauthor
  47. Schlieper A, Rowe PC, Orrbine E, Soubek M, Clark WF, Wolfish N, Mclaine PN. Cognitive and behavioural sequelae of the hemolytic uremic syndrome (HUS).; 1992. Clinical & Investigative Medicine (Suppl) A#660,15:A107,1992. Coauthor
  48. Clark WF, Parbtani A, Huff MW, Muirhead N, Holub BJ, Philbrick DJ, Kreeft J, Naylor CD. Double-blind crossover study of fish oil dietary supplementation in systemic lupus erythematosus (SLE).; 1992. Clinical & Investigative Medicine (Suppl A) A#596,15:A97,1992. Principal Author
  49. Hall AV, Parbtani A, Clark WF, Keeney M, Chin-Yee I, Holub BJ, Philbrick DJ. Amelioration of MRL/lpr lupus nephritis by dietary flaxseed lignan.; 1992. Clinical & Investigative Medicine (Suppl) A#558,15:A91,1992. Coauthor
  50. Hall AV, Parbtani A, Clark WF, Keeney M, Chin-Yee I, Philbrick DJ, Holub BJ. Effects of flaxseed lignans (PAF-antagonist) on the nephritis of the MRL/lpr lupus mice.; 1992. Book of Abstracts of the 3rd International Conference on Systemic Lupus Erythematosus 1:48,1992. Coauthor
  51. Clark WF, Parbtani A, Huff, MW, Muirhead N, Holub BJ. Double-blind crossover study of fish oil therapy in patients with lupus erythematosus.; 1992. Book of Abstracts of  the 3rd International Conference on Systemic lupus Erythematosus 1:21,1992-Themed poster. Principal Author
  52. Hall AV, Linton AK, Lindsay RM, Clark WF. Pulmonary capillary wedge pressure (PCWP) determines fluid replacement requirements during continuous arteriovenous hemodialysis.; 1991. Journal of the American Society of Nephrology 2:647,1991. Senior Responsible Author
  53. Hall AV, Linton AL, Lindsay RM, Clark WF. Continuous arteriovenous hemodialysis (CAVHD) for acetaminophen-induced acute renal failure.; 1991. Journal of the American Society of Nephrology 2:307,1991. Senior Responsible Author
  54. Clark WF, Hall AV, Parbtani A, Huff M, Philbrick D, Spanner E, Holub BJ. The effect of fish oil dietary supplementation of the dyslipidemia and coagulopathy of patients with primary nephritic syndrome.; 1991. Journal of the American Society of Nephrology 2:234,1991. Principal Author
  55. Clark WF, Rock GA, Buskard N, Leblond P, Shumak K, Sutton D and the Canadian Apheresis Study Group. Trends in therapeutic apheresis in Canada from 1982-1990.; 1991. Clinical & Investigative Medicine 14:A63,1991. Principal Author
  56. Clark WF, Parbtani A, Philbrick D, Huff M, Holub BJ. Effects of fish oil in the chronic remnant nephron model.; 1990. Journal of the American Society of Nephrology 1:439,1990. Principal Author
  57. Clark WF, Parbtani A, Holub B, Huff M, Falardeau P. Omega-3 fatty acid dietary supplementation in lupus nephritis.; 1989. American Journal of Kidney Diseases XIV:432,1989. Principal Author
  58. Parbtani A, Clark WF. Indicators of Renal Function.; 1989. Canadian Association of Laboratory Animal Sciences 28:3,1989. Senior Responsible Author
  59. Clark WF, Parbtani A, Holub B, Huff M, Falardeau P. Omega-3 fatty acid dietary supplementation in lupus nephritis.; 1988. Nutrient Modulation of Progressive Renal Injury 55,1988. Principal Author
  60. Clark WF, Parbtani A, Holub B, Huff M, Falardeau P. Omega-3 fatty acid dietary supplementation in lupus nephritis.; 1988. The American Society of Nephrology 220A:(no65),1988. Principal Author
  61. Muirhead N, Keown PA, Mazaheri R, Jevnikar AM, Hollomby DJ, Hodsman AB, Cordy PE, Lindsay RM, Clark WF, Faye WP. Recombinant human erythropoietin (r-HuEPO) in the anemia of chronic renal failure: A pharmokinetc study.; 1988. Clinical & Investigative Medicine 11:C85(noR-546),1988. Coauthor
  62. Parbtani A, Clark WF, Holub B, Philbrick D, Gieber S, Reid B, Macdonald JWD. Comparative efficacies of fish oil diet (FOD), safflower oil diet (SOD), a stable prostacyclin (iloprost) and a thromboxane synthase inhibitor (TSI) in NZB/W F1 mice.; 1988. Clinical & Investigative Medicine 11:C83,1988. Co-Principal Author
  63. Clark WF, Parbtani A, Philbrick D, Smallbone B, Geiber S, Mcdonald JWD. Comparative efficacy with fish oil or iloprost in the remnant nephron model.; 1988. Clinical & Investigative Medicine 11:C82(noC-526),1988. Principal Author
  64. Jevnikar AM, Petric R, Holub B, Philbrick D, Linton AL, Clark WF. Effect of dietary fish oil on cyclosporine (CSA) nephrotoxicity and associated hyperlipidemia.; 1988. Clinical & Investigative Medicine 11:C82(noC0525),1988. Senior Responsible Author
  65. Muirhead N, Keown PA, Mazaheri R, Jevnikar AM, Hollomby DJ, Hodsman AB, Cordy PE, Lindsay RM, Faye WP, Clark WF. A randomized double-blind controlled trial of recombinant human erythropoietin (r-HuEPO) in the anemia of hemodialysis patients.; 1988. Clinical & Investigative Medicine 11:C79(noR-508),1988. Senior Responsible Author
  66. Clark WF, Parbtani A, Holub B, Mcdonald JWD, Reid B. Dietary fish oil in lupus nephritis.; 1988. Clinical & Investigative Medicine 11:C78(noR-501),1988. Principal Author
  67. Clark WF, Parbtani A, Jevnikar A. Fish oil therapy in kidney disorders.; 1988. Health Effects of Fish and Fish Oils 10,1988. Principal Author
  68. Parbtani A, Clark WF, Mcdonald JWD. Prostaglandin (PG) analogues reverse nephritis and reduce mortality in NZB/W F1 lupus mice.; 1988. United States and Canadian Academy of Pathology 70A(no417),1988. Coauthor
  69. Clark WF, Parbtani A, Mcdonald JWD, Holub B. The effects of fish oil (eicosapentaenoic acid) on progression of renal failure in the 5/6 nephrectomized rat.; 1988. United States and Canadian Academy of Pathology 18A(no103),1988. Principal Author
  70. Parbtani A, Clark WF, Macdonald JWD. Reversal of proteinuria and reduction of mortality in NZB/W F1 lupus mice by prostaglandin E(PGE) iloprost and thromboxane synthase inhibitor (TSI).; 1988. Kidney International 33:321,1988. Coauthor
  71. Parbtani A, Clark WF, Macdonald JWD. Reversal of proteinuria and reduction of mortality in NZB/W F1 lupus mice by prostaglandin E(PGE) iloprost and thromboxane synthase inhibitor (TSI).; 1987. American Society of Nephrology 20:174A,1987. Coauthor
  72. Clark WF, Parbtani A, Mcdonald JWD, Taylor N, Turnbull DI. Prostaglandins in experimental lupus nephritis.; 1986. American Society of Nephrology 19:159A,1986. Principal Author
  73. Clark WF, Parbtani A, Tevaarwerk GJM, Linton AL. Prostaglandins in experimental lupus nephritis.; 1986. Clinical & Investigative Medicine 9:A112,1986. Principal Author
  74. Clark WF, Tevaarwerk GJM, Reid D, Hall S, Parbtani A, Kreeft J. A calcium-dependent Fc receptor on human platelets.; 1986. Clinical & Investigative Medicine 9:A82,1986. Principal Author
  75. Parbtani A, Clark WF, Caveney A, Reid B, Tevaarwerk GJM. Deaggregation of human platelets in inhibited by heat aggregated IgG.; 1986. Clinical & Investigative Medicine 9:A77,1986. Coauthor
  76. Cattran DC, Dossetor J, Keown P, Stiller C, Halloran P, Clark WF. Cyclosporin (9Cy) treatment of patients (P) with glomerulonephritis (GN).; 1985. American Society of Nephrology 18:33A,1985. Senior Responsible Author
  77. Tevaarwerk GJM, Clark WF, Plomley RF, Hall SM. Platelet surface-associated immunoglobulin-G in normal men and women with the effect of oral contraceptives: an investigation into the stoichiometry of platelet surface associated IgG measurement by radioimmunometric assay.; 1985. Clinical & Investigative Medicine 8:A123,1985. Coauthor
  78. Clark WF, Tevaarwerk GJM, Hall SM. Platelet surface-associated immunoglobulin-G in patients with systemic lupus erythematosus treated with and without plasma exchange.; 1985. Clinical & Investigative Medicine 8:A123,1985. Principal Author
  79. Clark WF, Tevaarwerk GJM, Plomley RF, Reid BD, Parbtani A. Immunoglobulin-G is an agonist of human platelet release – mechanisms of action.; 1985. Clinical & Investigative Medicine 8:A123,1985. Principal Author
  80. Clark WF, Balfe JW, Cattran DC, Williams W, Koval JJ, Arnott M, Chodirker WB, Lindsay RM, Linton AL. A controlled study of long term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis.; 1984. Annals of Internal Medicine (special issue – 1st International meeting on Hemapheresis) 135:21,1984. Principal Author
  81. Riche BE, Plomley RF, Bell DA, Harth M, Clark WF. Intraplatelet serotonin concentrations in SLE.; 1984. Kidney International 25:993,1984. Senior Responsible Author
  82. Plomely RF, Clark WF, Tevaarwerk GJM, Riche BR, Wells GA. Platelet associated IgG and platelet serotonin in SLE: renal and non-renal.; 1984. Kidney International 25:226,1984. Coauthor
  83. Clark WF, Williams W, Cattran DC, Balfe JW, Chodirker WB, Koval JJ, Lindsay RM, Linton AL. A controlled trial of chronic plasma exchange therapy in SLE.; 1984. Kidney International 25:161,1984. Principal Author
  84. Plomley RF, Clark WF, Tevaarwerk GJM, Riche BR, Wells GA. Platelet associated IgG and platelet serotonin in SLE: renal and non-renal.; 1983. American Society of Nephrology 89A,1983. Coauthor
  85. Clark WF, Williams W, Cattran DC, Balfe JW, Chodirker WB, Koval JJ, Lindsay RM, Linton AL. A controlled trial of chronic plasma exchange therapy in SLE nephritis.; 1983. American Society of Nephrology 24A,1983. Principal Author
  86. Clark WF, Willliams W, Cattran DC, Balfe JW, Chodirker WB, Koval JJ, Lindsay RM, Linton AL. A controlled trial of chronic plasma exchange in SLE nephritis.; 1983. Clinical & Investigative Medicine 6:(suppl. 2)54,1983. Principal Author
  87. Clark WF, Tevaarwerk GJM, Reid BD, Plomley RF. A model of human platelet immune complex interaction.; 1983. Clinical & Investigative Medicine 6:(suppl. 2)54,1983. Principal Author
  88. Riche BR, Plamley RF, Bell DA, Harth M, Clark WF. Intraplatelet serotonin concentrations in SLE.; 1983. Canadian Society of Nephrology 18,1983. Senior Responsible Author
  89. Clark WF, Williams W, Cattran DC, Balfe JW, Chodirker WB, Koval JJ, Lindsay RM, Linton AL:. A controlled trial of chronic plasma exchange therapy in SLE nephritis.; 1983. Canadian Society of Nephrology 6,1983. Principal Author
  90. Riche BR, Plomley RF, Bell DA, Harth M, Clark WF. Intraplatelet serotonin concentrations in SLE.; 1983. Annals of the Royal College of Physicians & Surgeons 16:379,1983. Senior Responsible Author
  91. Clark WF, Tevaarwerk GJM, Reid BD. A mechanism of glomerular immune complex localization.; 1983. Kidney International 23:180,1983. Principal Author
  92. Clark WF, Tevaarwerk GJM, Reid BD. A mechanism of glomerular immune complex localization.; 1982. American Society of Nephrology 87A,1982. Principal Author
  93. Clark WF, Willliams W, Cattran DC, Chodirker WB, Koval JJ, Lindsay RM, Linton AL. Controlled trial of chronic plasma exchange therapy in SLE nephritis.; 1982. Kidney International 21:147,1982. Principal Author
  94. Linton AL, Cattran D, Chodirker WB, Williams W, Clark WF. Controlled trial of plasma exchange (PE) in SLE.; 1981. Western Dialysis and Transplant Society viii,1981. Senior Responsible Author
  95. Clark WF, Williams W, Cattran DC, Chodirker WB, Koval JJ, Lindsay RM, Linton AL. Controlled trail of chronic plasma exchange therapy in SLE nephritis.; 1981. American Society of Nephrology 20A,1981. Principal Author
  96. Clark WF, Reid BD, Tevaarwerk GJM. Human immune complex-platelet interaction in systemic lupus erythematosus.; 1981. Annals of the Royal College of Physicians & Surgeons of Canada 14:196,1981. Principal Author
  97. Rush DN, Clark WF, Banerjee D, Keown PA:. Fc-receptor mediated human monocyte chemiluminescence.; 1981. Clinical & Investigative Medicine 4:29B,1981. Coauthor
  98. Lamki LM, Driedger AA, Linton AL, Clark WF, Turnbull DI, Lindsay RM. Renal uptake of 67k-gallium in drug-induced interstitial nephritis and other causes of acute renal failure.; 1981. American Roentogen Ray Society 102,1981. Coauthor
  99. Linton AL, Clark WF, Lindsay RM. Acute interstitial nephritis due to drugs.; 1981. Kidney International 19:131,1981. Coauthor
  100. Lindsay RM, Clark WF, Linton AL. Variable heparin requirements during dialysis.; 1981. Kidney International 19:392,1981. Coauthor
  101. Clark WF, Lindsay RM, Cattran DC, Chodirker WB, Barnes CC, Koval JJ, Linton AL. Monthly plasmapheresis in the treatment of systemic lupus erythematosus with diffuse proliferatvie glomerulonephritis: A pilot study.; 1981. Kidney International 19:389,1981. Principal Author
  102. Bailey RR, Werb R, Lindsay RM, Clark WF, Linton AL. Different effects of prostaglandin-E2 in two models of experimental acute renal failure.; 1980. Australasian New Zealand Journal of Medicine 10:128-129,1980. Coauthor
  103. Linton AL, Clark WF, Lindsay RM:. Acute interstitial nephritis due to drugs.; 1980. American Society of Nephrology 24A,1980. Coauthor
  104. Lindsay RM, Dennis B, Clark WF, Linton AL. The effect of gel filtrations on platelets from normal and uremic individuals.; 1980. Clinical Research 28:697A,1980. Coauthor
  105. Clark WF, Tevaarwerk GJM, Reid BD. Platelet aggregation and release associated with immune complex formation in pig plasma.; 1980. Clinical Research 28:682A,1980. Principal Author
  106. Clark WF, Lindsay RM, Chodirker WB, Cattran DC, Linton AL. Elective plasmapheresis in SLE nephritis: pilot for a controlled prospective study.; 1979. Kidney International  16:928,1979. Principal Author
  107. Bailey RR, Werb R, Lindsay RM, Clark WF, Linton AL. Different effects of prostaglandin-E2 in two models of experimental acute renal failure.; 1979. New Zealand Medical Journal 89:232,1979. Coauthor
  108. Clark WF, Lindsay RM, Chodirker WB, Cattran DC, Linton AL. Elective plasmapheresis is SLE nephritis: pilot for a controlled prospective study.; 1979. American Society of Nephrology 158A,1979. Principal Author
  109. Werb R, Lindsay RM, Clark WF, Linton AL. Serum vitamin A levels in patients on regular hemodialysis: Associated finding s in response to treatment.; 1979. Western Dialysis and Transplant Society 47,1979. Coauthor
  110. Lindsay RM, Clark WF, Linton AL. Variable heparin requirements during dialysis.; 1979. Western Dialysis and Transplant Society 44,1979. Coauthor
  111. Lindsay RM, Cvejich L, Clark WF, Linton AL. The evaluation of a combined hemodialysis-hemoperfusion system.; 1979. Western Dialysis and Transplant Society 43,1979. Coauthor
  112. Kinlock RD, Austin TW, Clark WF, Shearer RS. A clinical trial of Cinoxacin in urinary tract infections.; 1979. Annals of the Royal College of Physicians & Surgeons of Canada 54,1979. Coauthor
  113. Clark WF, Turnbull DI, Lindsay RM, Linton AL. Immune complex deposition and scarring I the mesangial and subendothelial system of the kidney.; 1978. Clinical Research 26:868A,1978. Principal Author
  114. Lindsay RM, Aronstam A, Dennis B, Friesen MH, Clark WF, Linton AL. Platelet factor 4 activity in patients on maintenance hemodialysis.; 1978. Kidney International 13:441,1978. Coauthor
  115. Kinloch RD, Clark WF, Lindsay RM, Linton AL. Furosemide and normal saline in the treatment of the syndrome of inappropriate ADH.; 1978. Kidney International 131:441,1978. Coauthor
  116. Clark WF, Linton AL, Cordy PE, Keown PA, Lohmann RC, Linsday RM. Thrombocytopenia, immunological tests and disease activity in lupus nephritis.; 1978. Kidney International 13:439,1978. Principal Author
  117. Lindsay RM, Aronstam A, Dennis B, Friesen MJ, Clark WF, Lindon AL. Platelet factor 4 activity in patients on maintenance hemodialysis.; 1978. Annals of the Royal College of Physicians & Surgeons of Canada 88,1978. Coauthor
  118. Clark WF, Linton AL, Cordy PE, Keown PA, Lohmann RC, Lindsay RM. Thrombocytopenia, immunological tests and disease activity in lupus nephritis.; 1978. Annals of the Royal college of Physicians & Surgeons of Canada 86,1978. Principal Author
  119. Lindsay RM, Aronstam A, Dennis B, Friesen MJ, Clark WF, Linton AL. Platelet factor 4 activity in patients on maintenance hemodialysis.; 1977. American Society of Nephrology 32A,1977. Coauthor
  120. Lindsay RM, Friesen MJ, Southcott D, Clark WF, Aronstam A, Linton AL. In vitro platelet foreign surface interaction  with oxygenator membranes.; 1977. American Society for Artificial Internal Organs 50,1977. Coauthor
  121. Friesen MJ, Clark WF, Aronstam A, Linton AL, Lindsay RM. Platelet function in SLE nephritis.; 1977. Annals of the Royal College of Physicians & Surgeons of Canada 74,1977. Coauthor
  122. Lindsay RM, Friesen MJ, Southcott D, Clark WF, Aronstam A Linton AL. In vitro platelet-foreign surface interactions with oxygenator membranes.; 1976. Clinical Research 1976. Coauthor
  123. Friesen MJ, Clark WF, Aronstam A, Linton AL, Lindsay RM. Platelet function in SLE nephritis.; 1976. American Society of Nephrology 16,1976. Coauthor
  124. Linton AL, Friesen MJ, Clark WF, Lindsay RM. Platelet abnormalities in SLE nephritis.; 1976. Australasian Society of Nephrology 1976. Coauthor
  125. Linton AL, Lindsay RM, Clark WF, Driedger AA. Blood loss studies in the investigation of anemia in regular dialysis treatment.; 1976. Annals of the Royal College of Physicians & Surgeons of Canada 68,1976. Coauthor
  126. Clark WF, Lewis ML, Cameron JS, Linton AL. Association of intrarenal platelet consumption with tissue damage in the nephritis of SLE.; 1976. Annals of the Royal College of Physicians & Surgeons of Canada 65,1976. Principal Author
  127. Lindsay RM, Clark WF, Driedger AA, Linton AL. The importance of blood loss studies in the investigation of anemia in regular dialysis treatment.; 1975. American Society of Artificial Internal Organs 37,1975. Coauthor
  128. Clark WF, Lewis ML, Cameron JS, Parsons V. Turnover and distribution of platelets in patients with lupus nephritis.; 1974. Kidney International 256, 1974. Principal Author

Abstracts Presented

  1. Clark WF, Macnab JJ, Sontrop JM, Jain AK, Moist  L, Suri R, Garg AX. Simple screening strategy to identify rapid renal decline in the general population, World Congress of Nephrology,Chronic Kidney Disease: Pathogenesis, Epidemiology, Prevention, Consequences: Treatment and Prevention of CKD, OR#28, pg 160; April 8-12, 2011, International Society of Nephrology, Vancouver, British Columbia, Canada, Presenter
  2. Clark WF, Microalbuminuria as a Marker of CKD Prognosis, Basic and Clinical Science Symposium. The 43rd Annual Meeting of the American Society of Nephrology. November 18-21, 2010, American Society of Nephrology, Denver, Colorado, United States, Invited Lecturer
  3. Clark WF, Na Y, Rosansky SJ, Sontrop JM, Macnab JJ, Glassock RJ, Eggers P, Jackson K, Moist L. Higher eGFR at Dialysis Initiation is Associated with Increased Mortality. TH-FC044, Epidemiology and Outcomes. The 43rd Annual Meeting of the American Society of Nephrology. November 18-21, 2010, American Society of Nephrology, Denver, Colorado, United States
  4. Clark WF, Sontrop JS, Macnab JJ, Salvadori M, Moist L, Suri R, Garg AX. Long-term Risk for Hypertension, Renal Impairment and Cardiovascular Disease after Exposure to Drinking Water Contaminated with E.coli O157:H7: Findings from a Prospective Cohort Study. Canadian Society of Nephrology, Montreal, Quebec, Canada, Presenter
  5. Clark WF, Na Y, Rosansky SJ, Sontrop JM, Macnab JJ, Glassock RJ, Eggers P, Jackson K, Moist L. Early Dialysis Initiation is Associated with Increased Mortality. Canadian Society of Nephrology, Montreal, Quebec, Canada, Presenter
  6. Clark WF, Macnab JJ, Sontrop JM, Moist L, Jain AK, Salvadori M, Suri R, Garg AX. University of Western Ontario, Identifying Patients with Rapid Renal Decline in a Community-Based Population. Canadian Society of Nephrology, Montreal, Quebec, Canada, Presenter
  7. Clark WF, Sontrop JS, Macnab JJ, Moist L, Salvadori M, Suri R and Garg AX, Long-Term Risk for Hypertension and Renal Impairment after Exposure to Drinking Water Contaminated with E.coli O157:H7: Findings from teh Walkerton Health Study. TH-PO543, American Society of Nephrology, San Diego, California, United States, Presenter
  8. Prabhu C, Sontrop JS, Macnab JJ, Clark WF. The Prevalence of Undetected Chronic Kidney Disease in a Rural Canadian Community, F-PO1606, American Society of Nephrology, San Diego, California, United States, collaborator
  9. Clark WF, Macnab JJ, Sontrop J, Moist L, Suri R, Garg A. London , ON, A Longitudinal Study on the Rate of Renal Decline in a Community-Based Population. SA-PO2767, American Society of Nephrology, San DIego, California, United States, Presenter
  10. Rosansky SJ, Eggers PW, Clark WF, Glassock RJ. Columbia, SC, The Steady Rise in MDRD eGFR for Patients Initiating Hemodialysis 1996 - 2005 in the USA, F-PO1453, American Society of Nephrology, San Diego, California, United States, collaborator
  11. Marshall JK, Post-Infective Dyspepsia Eight Years After the Walkerton Outbreak of Waterborne Gastrenteritis (GE), Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK, Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON; Division of Nephrology and Kidney Research Unit, University of Western Ontario, London, ON, Digestive Disease Week, Chicago, Illinois, United States, Co-Author
  12. Clark WF. Introduction to Symposium 2008, HUS/TTP Update - 2008 Symposium, London, Ontario, Canada, Presenter
  13. Weir MA, Sontrop JM, Clark WF. Fluid loading causes an increase in urinary protein excretion. May 28-June1, 2008, Canadian Society of Nephrology, London, Ontario, Canada, collaborator
  14. Garg AX, Salvadori M, Okell JM, Thiessen-Philbrook HR, Suri RS, Filler G, Moist LM, Matsell D, Clark WF. Absence of Major Renal Sequelae 5 Years after E.coli 0157 Hemolytic Uremic Syndrome. SA-PO882. American Society of Nephrology, San Francisco, California, United States
  15. Forzley B, Sontrop J, Chen SJ, Enright J, Clark WF. Critical Facors in Treating TTP/HUS with Plasma Exchange: A Single Centre 25 Year Experience. SU-PO918, American Society of Nephrology, San Francisco, California, United States
  16. Wyllie MA, Kortas CM, Garg AX, Clark WF. Large Fluid Intake Acutely Incduces a Reversible Increase in Gamma-Globulin Excretion in Normal Subjects. Canadian Society of Nephrology, Halifax, Nova Scotia, Canada
  17. Forzley BR, Enright J, Chen S, Lockwood K, Clark WF. Two Prognostic Indicies in Hemolytic Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP), Using 118 Cases at a Single Centre, Canadian Society of Nephrology, Halifax, Nova Scotia, Canada
  18. Forzley BR, Enright J, Chen SJ, Lockwood K, Clark WF, Assessing Treatment in 118 Cases of Hemolytic Uremic Syndrome (HUS) / Thropmbocytopenic Purpura (TTP) in a Single Centre, Canadian Society of Nephrology, Halifax, Nova Scotia, Canada
  19. Forzley BR, Enright J, Chen SJ, Lockwood K, Clark WF. Assessing Treatment in 118 Cases of Hemolytic Uremic Syndrome (HUS)/Thrombotic Thrombocytopenic Purpura (TTP) in a Single Centre. Abst. #068, Canadian Society of Nephrology. Halifax, Nova Scotia
  20. Forzley BR, Enright J, Chen SJ, Lockwood K, Clark WF. Two Prognostic Indicies in Hemolytic Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP), using 118 Cases at a Single Centre. Abst. #067, Canadian Society of Nephrology, Halifax, Nova Scotia
  21. Weir MA, Kortas CM, Garg AX, Clark WF. Large Fluid Intake Acutely Induces a Reversible Increase in Gamma-Globulin Excretion in Normal Subjects. Abst. #056, Canadian Society of Nephrology, Halifax, Nova Scotia
  22. Clark WF, Macnab JJ, Chen SJ, Suri RS, Moist LM, Garg AX. K/DOQI And Prevalence Of Chronic Kidney Disease In A Community. Abst. # 067, Canadian Society of Nephrology, Quebec
  23. Garg AX, Clark WF, Thiessen-Philbrook HR, Salvadori M and Matsell D on behalf of the Walkerton Health Study Investigators. Absence Of Renal Sequelae After Childhood E. Coli 0157:H7 Gastroenteritis. Abst. # 058, Canadian Society of Nephrology, Quebec
  24. Clark WF,  Kortas C, Moist LM, Suri RS, Macnab JJ, Salvadori M, Weir MA, Duwyn R, Garg AX. Chronic High Fluid Intake May Be Injurious To Your Kidneys. Abst. # 021, Canadian Society of Nephrology, Quebec
  25. Macnab JJ, Clark WF. Age and Sex Specific Reference Ranges for Systolic Diastolic and Pulse Pressure and Within Subject Variability of 3 Repeated Blood Pressure Measurements. Proceedings of Canadian Cardiovascular Congress. Canadian Hypertension Society, Calgary, Alberta
  26. Rock G, Sutton DM, Sternbach M, Benny B, Clark WF, Anderon D. Plasma therapy in thrombotic thrombocytopenic purpura (TTP). Abstracts Book,  9: Abst # L74 (Sept) 2002. 9th Congress of the World Apheresis Association, Paris, France
  27. Clark WF, Rock GA, Garg AX and Members of The Canadian Aphresis Group. Abstracts Book, Abst # L164 (Sept) 2002. 9th Congress of the World Apheresis Association, Paris, France
  28. Flaxseed: A nutraceutical for lupus nephritis? 13:82,1995. International Society of Nephrology, Clark WF, Parbtani A, Huff MW, Spanner E, Philbrick D, Holub BJ.
  29. Parbtani A, Clark WF, De Salis H, Philbrick DJ, Holub BJ. Flaxseed and its constituents in murin lupus. A#9,11,1994. 7th International Congress on Nutrition and Metabolism in Renal Disease
  30. Clark WF-Chairman, Treatment of Lupus Nephritis (1). 3rd International Conference on Systemic Lupus Erythematosus, Lupus Nephritis workshop, London, United Kingdom
  31. Clark WF, Treatment of Lupus Nephritis (3) – eicosapentaenois acid. Nephrology 2,3(1991)234. 3rd International Conference on Systemic Lupus Erythematosus, Lupus Nephritis workshop, London, United Kingdom
  32. Clark WF, Tevaarwerk GJM, Reid BD. Mechanisms of intra-renal platelet release. International Symposium on Monitoring and Manipulation in Autoimmune Disease and Organ Transplantation
  33. Clark WF, Cattran DC, Balfe JW, Williams W, Linsday RM, Linton AL. Chronic plasma exchange in SLE nephritis. 24,1983. XXth Congress of the European Dialysis and Transplant Association
  34. Clark WF, Cattran DC, Williams W, Balfe JW, Koval JJ, Chodirker WV, Lindsay RM, Linton AL. Controlled trial of chronic plasma exchange therapy in SLE nephritis. 148,1982. Fourth Annual Apheresis Symposium: Current Concepts and Future Trends
  35. Clark WF, Williams W, Cattran, DC Chodirker WB, Koval JJ, Lindsay RM, Linton AL. Controlled trial of chronic plasma exchange therapy in SLE nephritis. Haemonetics Research Institute, 1982. 9th Annual International Advance Apheresis Seminar
  36. Clark WF, Turnbull DI, Lindsay RM, Linton AL. Platelet studies in experimental endo-capillary scarring induced in swine by precipitating immune complexes. K-11.1978, VIIth International Congress of Nephrology
  37. Werb R, Clark WF, Lindsay RM, Jones EOP, Turnbull DI, Linton AL. Protective effect of PGE-2 in experimental acute renal failure (ARF). K-9,1978. VIIth International Congress of Nephrology
  38. Clark WF, Turnbull DI, McCallum JA, Lindsay RM, Linton AL. Glomerular endocapillary scarring induced by precipitating immune complexes in swine: light, ultrastructural and immunofluorescent studies. K-1,1978. VIIth International Congress of Nephrology
  39. Lindsay RM, Aronstam A, Oreopoulos D, Clark WF, Linton AL. Plasma heparin neutralizing activity (HJA) in dialyzed and non-dialyzed uremics. I-8,1978. VIIth International Congress of Nephrology
  40. Lindsay RM, Friesen M, Aronstam A, Clark WF, Linton AL. Improvement of platelet function by increased frequency of dialysis. I-8,1978. VIIth International Congress of Nephrology
  41. Werb R, Clark WF, Lindsay RM, Jones EOP, Linton AL. Serum vitamin A levels associated findings in patients on regular haemodialysis treatment. D-14,1978. VIIth International Congress of Nephrology
  42. Werb R, Lindsay RM, Clark WF, Sibbald WJ, Linton AL. Aetiology, diagnosis, treatment and prognosis of acute renal failure (ARF) in an intensive care unit. 3:146,1977. 2nd World Congress on Intensive Care
  43. Sherwin L, Lindsay RM, Turnbull DI, Clark WF, Linton AL. A study of 100 cases of primary glomerular disease. 587,1975. VIth International  Congress of Nephrology
  44. Clark WF, Sontrop JM, Macnan JJ, Suri R, Moist LM, Salvadori MI, Garg AX. Urine Volume and Renal Decline: Resultsfrom a Community-based Cohort Study. ASN, Philadelphia, PA, USA.908-CKD, AKI, DM Clinical: Other Kidney/Urological Disorders, Epi, Outcomes, Clinical Trials, Health Services, Ethics; Abstract #20055, American Society fo Nephrology, United States, Presenter
  45. Clark WF, Na Y, Rosansky SJ, Sontrop JM, Macnab JJ, Glassock RJ, Eggers PW, Jackson KL, Moist LM. Higher eGFR at Dialysis is Associated with Increased Mortality, TH-FC044;Dialysis:Epidemiology and Outcomes. The 43rd Annual Meeting of the American Society of Nephrology, Denver, Colorado, U.S.A. November 18, 2010. ASN, Denver, Colorado, United States, Presenter
  46. Clark WF, Microalbuminuria as a Marker of CKD Prognosis, ASN, Renal Week 2010, Denver, Colorado, United States, Invited Lecturer
  47. Sontrop JM, Suri RS, Sultan NM, Macnab JJ, Moist L, Clark WF. Polyuria is a major risk factor for proteinuria in the general population. May 28-June1, 2008, Canadian Society of Nephrology, London, Ontario, Canada, Co-Author

Posters Presented

  1. Clark WF, Association between water intake, chronic kidney disease, and cardiovascular disease: A cross-sectional analysis of NHANES data, M0072, ISN World Congress of Nephrology, Hong Kong, Hainan, China, Presenter
  2. Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Duhein O, Huang SS, Clark WF, Association between water intake, chronic kidney disease, and cardiovascular disease: A cross-sectional analysis of NHANES data, Canadian Society of Nephrology, Montreal, Quebec, Canada, Presenter
  3. Clark WF, Sontrop JM, Macnab JJ, Suri R, Moist L, Salvadori M, Garg AX. Urine Volume and Renal Decline: Results from a Community-Based Cohort Study, TH-PO385; November 10, 2011:  Kidney Week, Philadelphia, American Society of Nephrology - Kidney Week 2011, Philadelphia, Pennsylvania, United States, Presenter
  4. Rosansky SJ, Hardin JW, Richards F, Haddock KS, O’Hare AM and Clark WF. The relationship of urine proteinuria to outpatient “AKI” and renal progression. FR-PO1380; November 11, 2011. Philadelphia Pennsylvania, U.S.A. American Society of Nephrology - Kidney Week 2011, Philadelphia, Pennsylvania, United States, Presenter
  5. Rosansky SJ, Hardin JW, Richards F, Haddock KS, O’Hare AM and Clark WF. Relationship between outpatient “AKI”, proteinuria, diagnosis diabetes, and rate of decline in renal function, nine years prior to dialysis initiation. PO; November 11, 2011. Philadelphia Pennsylvania, U.S.A. American Society of Nephrology - Kidney Week 2011, Philadelphia, Pennsylvania, United States, Presenter
  6. Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX. Urine Volume predicts rate of renal decline in a general population sample. 3rd North America Congress of Epidemiology. June 21-24,2011. Montreal, Quebec, Canada. North American Congress of Epidemiology, Montreal, Quebec, Canada, Presenter
  7. Clark WF, Macnab JJ, Sontrop JM, Moist L, Salvadori M, Suri R, Garg AX. Identifying Patients with Rapid Renal Decline in a Community-Based Population. F-PO1923; Progression of CKD, and CKD as a Risk Factor for Oucomes. The 43rd Annual Meeting of the American Society of Nephrology. November 18-21, 2010. American Society of Nephrology, Denver, Colorado, United States, Lead Investigator

Presentations

Invited Lectures

  1. Invited Lecturer, Department of Medicine, Schulich School of Medcine and Dentistry, London, Ontario, Canada, What do we know about CKD and water intake in MAN?? - HOW MUCH SHOULD YOU DRINK??? 2014 Sep 19, Presenters: Clark WF
  2. Invited Lecturer, Danone Nutricia Research, Santiago, Chile, What do we know about Kidney Health and increased fluid intake in Man? SLANH 2014 - Hydration and Kidney Disease Prevention, 2014 Aug 20, Presenters: Clark WF
  3. Invited Lecturer, Danone, Evian, Rhône, France, Increasing Water Intake in CKD: Why? Safe? Possible? Hydration 4 Health - 6th Annual Scientific Conference, 2014 Jul 2, Presenters: CLARK WF
  4. Invited Lecturer, International Congress on Nutrition and Metabolism in Renal Disease 2014, Wuerzburg, Germany, Increased Water Intake Slows Progression of CKD: Examination of Current Evidence, XVII International Congress, May 6-10, 2014, 2014 May 7, Presenters: Clark WF
  5. Invited Lecturer, Victoria Hospital - Department of Medicine, London, Ontario, Canada, Drink At Least 8 Glasses of Water a Day to Be Healthy: Really!!!! Sumner Auditorium, B2-119, Victoria Hospital, London Health Sciences Centre. 2014 Feb 21, Presenters: CLARK WF
  6. Invited Lecturer, Department of Medicine, London, Ontario, Canada, Water, How Much Is Enough? Medical Grand Rounds, University Hospital, London, Ontario, 2014 Jan 16, Hours: 1, Presenters: Clark WF
  7. Invited Lecturer, Nephrology Journal Club - London Health Sciences Centre, London, Ontario, Canada, What a Nephrologist needs to know about diagnosis and treatment of TMA. Black Trumpet, 523 Richmond Street 6:30 pm, 2013 Dec 10, Presenters: CLARK WF
  8. Panelist, American Society of Nephrology, Atlanta, Georgia, United States, Guidelines on the Use of Theapeutic Apheresis in Clinical Practice: An Evidence-Based Approach from the ASFA. Therapeutic Apheresis in Multiple Myeloma: Nay, American Society of Nephrology, Kidney Week, November 5-10, 2013. 2013 Nov 8, Presenters: Clark WF
  9. Invited Lecturer, American Society of Nephrology, Atlanta, Georgia, United States, Thrombotic Microangiopathies, American Society of Nephrology, Kidney Week, November 5-10, 2013. 2013 Nov 5, Presenters: Clark WF
  10. Invited Lecturer, Octapharma, Vancouver, British Columbia, Canada, Optimal treatment of Thrombotic Microangiopathy, 2013 Oct 18, Presenters: Clark WF
  11. Invited Lecturer, ISN World Congress of Nephrology, Hong Kong, Hainan, China, Drink at least eight glasses of water a day....really??? Industry Lunch Symposium, Danone/H4H, Hydration and Kidney DIsease Prevention, 2013 Jun 2, Presenters: Clark WF
  12. Invited Lecturer, Canadian Society of Nephrology, Montreal, Quebec, Canada, The Long and Winding Road of the Clinician Researcher, 2013 Apr 26, Presenters: Clark WF
  13. Invited Lecturer, Alexion, Hartford, Connecticut, United States, Walkerton - Longterm Complications of Haemolytic Uremic Syndrome, 2013 Mar 21, Presenters: Clark WF
  14. Invited Lecturer, Alexion, Hartford, Connecticut, United States, Thrombotic Microangiopathies - primary and secondary, 2013 Mar 21, Presenters: Clark WF
  15. Invited Lecturer, University of Saskatchewan, Regina, Saskatchewan, Canada, Plasma Exchange for Renal Disease, 2012 Nov 9, Presenters: Clark WF
  16. Invited Lecturer, University of Saskatchewan, Regina, Saskatchewan, Canada, Thrombotic Microangiopathies 2012. Diagnostic and Treatment Dilemna? 2012 Nov 8, Presenters: Clark WF
  17. Invited Lecturer, University of Manitoba - Faculty of Medicine, Section of Nephrology, Winnipeg, Manitoba, Canada, When should chronic dialysis be initiated? 2012 Jun 14, Presenters: Clark WF
  18. Invited Lecturer, Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada, Lupus Nephritis, Rheumatology Fellows Seminar, St. Joseph’s Health Care, London, ON. June 1, 2012. 2012 Jun 1, Presenters: Clark W. F.
  19. Invited Lecturer, The Center for Foodborne Illness Research and Prevention, Raleigh, North Carolina, United States, Assessing Long-term Sequelae using Registry-based Studies, Measuring Burden of Foodborne Disease With a Focus on Long-Term Health Outcomes. May 14-15, 2012, 2012 May 14, Presenters: Clark W. F.
  20. Invited Lecturer, Canadian Society of Nephrology, St. John’s, Newfoundland and Labrador, Canada, The 2011 European HUS epidemic: epidemiology, treatment, and lessons learned for Canada, Canadian Society of Nephrology, Annual General Meeting. April 25-29, 2012. 2012 Apr 28, Presenters: Clark W. F.
  21. Invited Lecturer, Sunnybrook Hospital - Nephrology, Toronto, Ontario, Canada, A Simple Overview: Plasmapheresis 1914-2011, Harrison Lecture Theatre, EG21. 2011 Dec 5, Presenters: Clark WF
  22. Invited Lecturer, American Renal Association, Las Vegas, Nevada, United States, Early Start of Dialysis, Annual Directors Meeting; Oct 20-21, 2011. 2011 Oct 21, Presenters: Clark WF
  23. Invited Lecturer, Charlottesville University, Charlottesville, Virginia, United States, Renal Indications for Therapeutic Apheresis: The Given and the Controversial from RPGN to Myeloma, Therapeutic Apheresis Academy 2011, Jordan Hall Conference Centre; Sept 22-24, 2011, 2011 Sep 23, Presenters: Clark WF
  24. Invited Lecturer, Charlottesville University, Charlottesville, Virginia, United States, Selective TherapeuticApheresis Modalities, Therapeutic Apheresis Academy 2011, Jordan Hall Conference Centre; Sept 22, 2011, 2011 Sep 22, Presenters: Clark WF
  25. Keynote Speaker, American Society of Apheresis, Scottsdale, Arizona, United States, Therapeutic Plasma Exchange for Multiple Myeloma - Cons. Annual General Meeting 2011;, 2011 Jun 4, Presenters: Clark WF
  26. Invited Lecturer, Gamma-Dynacare Medical Laboratories, London, Ontario, Canada, Kidney Disease - Cause and Prevention, 2009 Nov 17, Presenters: William Clark
  27. Invited Lecturer, American Society of Nephrology, San Diego, California, United States, “Secondary Thrombotic Microangiopathies”: Review of Microangiopathies and ADAMTS 13 Associated with Underlying Diseases (e.g. Malignant Hypertension, SLE, HIV, Drug Induced.), 2009 Oct 30, Presenters: Clark WF
  28. Invited Lecturer, IHLP Education Symposium, Stratford, Ontario, Canada, Walkerton Health Study, Rural Life and the Healthy Environment, Stratford, Ontario; May 6-8, 2009. 2009 May 7, Hours: 1, Presenters: Clark WF
  29. Invited Lecturer, Canadian Society of Nephrology, Edmonton, Alberta, Canada, Optimal Induction and Maintenance Therapy for Proliferative Lupus Nephritis, Canadian Society of Nephrology, Edmonton, Alberta; May, 2009, 2009 May, Hours: 1, Presenters: Clark WF
  30. Invited Lecturer, Canadian Apheresis Group, Ottawa, Ontario, Canada, Large Volume Plasma Exchange in TTP, Canadian Apheresis Group, Ottawa, Ontario; May 2009. 2009 May, Presenters: Clark WF
  31. Invited Lecturer, PEXIVAS Investigators, Cambridge, United Kingdom, Introduction to Plasma Exchange: History of trials of theraputic plasma exchange, PEXIVAS Investigators’ Meeting, Moller Centre, Churchill College, Cambridge UK. 2009 Apr 24, Hours: 0.5, Attendees: 43, Presenters: Clark WF
  32. Invited Lecturer, Credit Valley Hospital, Mississauga, Ontario, Canada, Commonest Indications for Plasma Exchange, 2009 Apr 14, Hours: 1, Presenters: Clark WF
  33. Invited Lecturer, CCECIA-IAU, Puerto Rico, Walkerton Health Study, Climate Change, Potable Water and Health, CECIA-IAU Symposium, Inter American University of Puerto Rico, Puerto Rico; Febuary 2009. 2009 Feb, Hours: 1, Presenters: Clark WF
  34. Presenter, EPA Symposium, Washington, District of Columbia, United States, Seven-year Longitudinal Study at Walkerton Ontario; The Walkerton Health Study, University of Western Ontario, 2008 Dec 2, Hours: 0.75, Presenters: Clark WF
  35. Presenter, EPA Symposium on Groundwater-Borne Infectious Disease, Etiologic Agents and Indicators, Washington, District of Columbia, United States, Discussion on Walkerton (eg. outbreak cost of illness for acute phase versus chronic sequellae disease, serendipitous findings?), University of Western Ontario, 2008 Dec 2, Hours: 0.5, Presenters: Clark WF
  36. Invited Lecturer, American Society of Nephrology, Philadelphia, Pennsylvania, United States, Timing of Dialysis: Is it K, T or V? Clinical Nephrology Conference; Nov.6, 2008. 2008 Nov 6, Presenters: Clark WF
  37. Invited Lecturer, Canadian Society of Nephrology, London, Ontario, Canada, Indications for Plasmapheresis, 2008 May 28, Presenters: Clark WF
  38. Invited Lecturer, New York Society of Nephrology, New York, New York, United States, Presenters: Clark WF.

Conference Presentation

  1. Expert, Alexion National Advisory Board, Toronto, Ontario, Canada, atypical HUS, Characterizing the eculizumab patient, 2013 Dec 13, Presenters: Clark WF
  2. Expert, Alexion National Advisory Board, Toronto, Ontario, Canada, atypical HUS, Enabling access to eculizumab, 2013 Dec 13, Presenters: Clark WF
  3. Invited Lecturer, San Diego, California, United States, Thrombotic Microangiopathies, 2012 Oct 30, Presenters: Clark WF
  4. Invited Lecturer, World Apheresis Association, Istanbul, Turkey, Plasma Exchange and Renal Disease: Evidence and Change. Plasma Exchange in Vasculitis Induced Renal Disease, 14th International Congress of World Apheresis Association and 7th National Congress of Turkish Society of Apheresis; Sept. 12-15, 2012; Istanbul, Turkey. 2012 Sep 15, Presenters: Clark WF
  5. Chair, World Apheresis Association, Istanbul, Turkey, Renal Disease and Vasculitis, 14th International Congress of World Apheresis Association and 7th National Congress of Turkish Society of Apheresis; Sept. 12-15, 2012; Istanbul, Turkey. 2012 Sep 15, Presenters: Clark WF, Cagirgan S, Kamali S.
  6. Invited Lecturer, American Society of Nephrology, Philadelphia, Pennsylvania, United States, Thrombotic Microangiopathy, Glomerular Disease Emergencies.Clinical Nephrology Conference, Kidney Week; Nov 12, 2011. 2011 Nov 12, Presenters: Clark WF
  7. Invited Lecturer, American Society of Nephrology, Philadelphia, Pennsylvania, United States, Thrombotic Microangiopathies, Glomerulonephritis Update: Diagnosis and Therapy 2011. Kidney Week ;Nov 8, 2011. 2011 Nov 8, Presenters: Clark WF
  8. Presenter, World Congress of Nephrology, Vancouver, British Columbia, Canada, A simple screening strategy to identify rapid renal decline in the general population. World Congress of Nephrology. Treatment and Prevention of CKD, OR28; April 10, 2011. Vancouver, British Columbia. 2011 Apr 10, Presenters: Clark WF

Guest presenter

  1. Presenter, Division of Nephrology - Nephrology Journal Club, London Health Sciences Centre, London, Ontario, Canada, Patient “PC”: aHUS in transplant patient, Teusdday September 30, 2014, 2014 Sep 30, Presenters: Clark WF

 

William Foster Clark

Professor

 

  • DEPARTMENTDepartment of Medicine
    Western University Canada
  • COUNTRYCANADA